



FOSUN PHARMA

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.*

(a joint st

Our Vision

We are committed to becoming a first-class enterprise in the global medical and healthcare market.


Our Mission

Better health for families worldwide.

Contents

02	C a I m
04	F a a H
05	M a m D a A a
48	S a D
56	I m C C a S a m L
57	I m C C a S a m C m I m
58	I m C C a S a m F a a
60	I m C C a S a m C a E
62	I m C C a S a m C a F
64	N I m C C a F a a I m
99	D

Corporate



Directors

Executive Directors

M. 吳以芳 (吳以芳) (Chairman)
M. 王可心 K (王可心) (Co-Chairman)¹
M. 關曉暉 G (關曉暉) (Vice-Chairman)²
M. 文德鏞 D (文德鏞) (Chief Executive Officer)³

Non-executive Directors

M. 陳啟宇 C (陳啟宇)
M. 姚方 F (姚方)
M. 徐曉亮 X (徐曉亮)
M. 潘東輝 D (潘東輝)

Independent Non-executive Directors

M. 李玲 L (李玲)
M. 湯谷良 G (湯谷良)
M. 王全弟 Q (王全弟)
M. 余梓山 S (余梓山)

Supervisors

M. 任倩 Q (任倩) (Chairman)
M. 曹根興 G (曹根興)
M. 管一民 G (管一民)

Joint Company Secretaries

M. 董曉嫻 D (董曉嫻)
M. 甘美霞 M (甘美霞)

Authorized Representatives

M. 吳以芳 Q (吳以芳)
M. 甘美霞 M (甘美霞)

Strategic Committee

M. 吳以芳 Q (吳以芳) (Chairman)⁴
M. 陳啟宇 C (陳啟宇)⁵
M. 姚方 F (姚方)
M. 徐曉亮 X (徐曉亮)
M. 李玲 L (李玲)

Audit Committee

M. 湯谷良 G (湯谷良) (Chairman)
M. 王全弟 Q (王全弟)
M. 李玲 L (李玲)

Nomination Committee

M. 王全弟 Q (王全弟) (Chairman)
M. 李玲 L (李玲)
M. 潘東輝 D (潘東輝)

Remuneration and Appraisal Committee

M. 余梓山 S (余梓山) (Chairman)
M. 湯谷良 G (湯谷良)
M. 王全弟 Q (王全弟)
M. 陳啟宇 C (陳啟宇)
M. 潘東輝 D (潘東輝)

Environmental, Social and Governance Committee

M. 余梓山 S (余梓山) (Chairman)
M. 李玲 L (李玲)
M. 吳以芳 Q (吳以芳)

Registered Office

9 F, N. 510 C, A
D
S, 200063, C

Principal Place of Business in the PRC

B A
N. 1289 A
S, 200233, C

¹ 吳以芳 於 2022 年 4 月 1 日獲委任為本公司之共同主席。
² 關曉暉 於 2022 年 1 月 1 日獲委任為本公司之副主席。
³ 文德鏞 於 2022 年 1 月 1 日獲委任為本公司之首席執行官。
⁴ 吳以芳 於 2022 年 1 月 1 日獲委任為本公司之主席。
⁵ 陳啟宇 於 2022 年 1 月 1 日獲委任為本公司之副主席。

⁴ 吳以芳 於 2022 年 1 月 1 日獲委任為本公司之主席。
⁵ 陳啟宇 於 2022 年 1 月 1 日獲委任為本公司之副主席。

Principal Place of Business in Hong Kong

5/F, Manulife Building
348 King's Road, Kowloon
Hong Kong

Legal Advisers in Hong Kong

Shum & Bak LLP

Legal Advisers in the PRC

Guangdong Law Firm (Shanghai Branch)

Auditors

EY & Partners
Certified Public Accountants
Registered Public Interest Entity Auditor
27/F, Manulife Building
979 King's Road, Kowloon
Hong Kong

Principal Banks

Industrial and Commercial Bank of China
Citibank
Industrial and Commercial Bank of China
Bank of China
Citibank
Shanghai Pudong Development Bank

Corporate Name

Shanghai Foreign Economic Cooperation (Group) Co., Ltd.*

Stock Abbreviation

FINHA.MA

Share Listing

Listing: Shanghai Stock Exchange
Stock Code: 600196
Listing: Shenzhen Stock Exchange
Stock Code: 02196

A Share Registrar and Transfer Office in the PRC

China Depository and Clearing Co., Ltd.
(CSDCC) Shanghai Branch
188 Zhongyuan Road
District
Shanghai, China

H Share Registrar and Transfer Office in Hong Kong

Intercontinental Ltd.
17/F, Finance House
16 Harbour Road
Hong Kong

Corporate Website

://www.finec.com

* Pursuant to the Listing Rules, the company is required to disclose its corporate name in the PRC. The company's corporate name in the PRC is Shanghai Foreign Economic Cooperation (Group) Co., Ltd. (Shanghai Foreign Economic Cooperation (Group) Co., Ltd.).

Financial H

For the six months ended 30 June

	2022 RMB million	2021 MB 卄 (卄)
Operating results		
	21,275	16,878
G	9,699	8,621
卄	1,999	1,343
卄	2,379	3,304
卄	1,554	2,482
EBI DA	3,881	4,670
Profitability		
G 卄	45.59%	51.08%
卄 卄	9.40%	7.96%
N 卄	8.79%	16.32%
Earnings per share (MB 卄)		
E卄 卄 卄	0.60	0.97
E卄 卄	0.60	0.97
Of which: Pharmaceutical manufacturing segment		
	14,271	12,179
G	7,762	6,965
卄 卄	1,890	1,353
卄 卄	1,579	1,257
	30 June 2022 RMB million	31 D 卄 2021 MB 卄
Assets		
卄 卄	98,754	93,237
E 卄 卄 卄	38,148	39,135
卄 卄	51,070	44,918
C卄 卄 卄 卄	12,258	10,308
D - 卄 卄	51.71%	48.18%

FINANCIAL REVIEW

D
 2021, 26.05%
 G
 MB21,275
 2021, 26.05%
 MB1,999
 MB1,820
 BN
 G
 2021, BN MB1
 D
 MB-260
 MB1,567
 MB1,307
 D
 MB1,554
 38.14% MB0.60
 G
 &D. D
 22.77%
 MB256 16.39%
 &D
 MB2,399
 MB1,818

REVENUE

D
 26.05%
 G
 MB7,592
 35.69%
 G
 MB21,275
 MB13,683
 G

Management

D A A

GROSS PROFIT

D 2021. G 12.50% MB9,699 MB8,621
 ; (1)
 ; (2)
 ; (3)
 G
 45.59%,
 5.49
 C
 G

SELLING AND DISTRIBUTION EXPENSES

D MB4,166 MB4,211 G MB45 1.07%
 19.58%, 5.37
 ; (1)
 ; (2)
 ; (3)
 H
 C
 G

R&D EXPENSES AND R&D EXPENDITURE

D MB2,399 G &D MB1,818
 22.77%. I &D
 MB256 16.39%. D
 MB2,062
 MB285 16.04%, 14.39%
 &D MB1,491 MB106 7.65%
 10.41%
 &D

OTHER GAINS AND OTHER EXPENSES

D MB1,645 G MB994 60.43% MB651
 BN
 D MB338 G MB573 169.53% MB911
 BN

SHARE OF PROFITS OF ASSOCIATES

D , A A A G A 2.92% MB899 m m
 MB926 m 2021.

PROFIT FOR THE PERIOD

D A A , G A 32.14%
 MB1,869 m m MB2,754 m 2021. m
 G A 2021 8.79% A 16.32%, .

PROFIT FOR THE PERIOD ATTRIBUTABLE TO OWNERS OF THE PARENT

D , G A A m MB1,999 m , A - -
 A MB656 m . A m A A A A BN
 G A A m A 2021, A m A A A
 A A A A BN A MB1 . D , A A
 m A A A A A , G A - - A MB1,567 m
 A A . D A A , G A A A
 A A m MB1,554 m , A - - A 37.39%.

DEBT STRUCTURE, LIQUIDITY AND SOURCES OF FUNDS

Total Debts

A A 30 J 2022, A G A MB30,461 m m MB25,299 m A A 31 D m 2021
 m . A A 30 J 2022, m - - - m G A
 41.76% A , A A 3.43 A A m A 38.33% A A 31 D m
 2021. D m - - - m A m A A m
 - A A . A A 30 J 2022, A A A A 18.92% MB12,258 m m
 MB10,308 m A A 31 D m 2021.

A A 30 J 2022, A m MB8,698 m (31 D m 2021: MB7,382 m) A
 G A m A , A m A A m MB.

A A 30 J 2022, A A A A A G m A m MB4,928 m (31
 D m 2021: MB4,276 m).

Management

D A A

	: m	C	: MB
	30 June 2022	31 D	m 2021
Cash and cash equivalents denominated in:			
MB	7,330		6,032
US\$	1,721		1,615
	2,220		1,907
HK\$	577		560
E	156		78
	254		116
	12,258		10,308

Gearing Ratio

As at 30 June 2022, the gearing ratio, which is the ratio of total debt to total capitalization, was 30.85%, compared to 27.13% as at 31 December 2021.

Interest Rate

As at 30 June 2022, the average interest rate on the outstanding debt was 4.5% (31 December 2021: MB7,968 million).

Maturity Structure of Outstanding Debts

	: m	C	: MB
	30 June 2022	31 D	m 2021
Within 1 year	17,740		15,602
1 to 2 years	4,648		5,067
2 to 5 years	5,753		2,073
Over 5 years	2,320		2,557
	30,461		25,299

Available Facilities

A ଚ 30 J 2022, ଚ ଚ ଚ ଚ ଚ MB12,258 ଲକ୍ଷ , G ଚ ଚ ଚ ଚ
 MB31,327 ଲକ୍ଷ ଚ ଚ ଚ G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .A
 ଚ ଚ ଚ ଚ ଚ ଚ ଚ G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ
 ଚ .A
 ଚ 30 J 2022, ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB57,845 ଲକ୍ଷ
 ଚ ଚ , MB26,518 ଲକ୍ଷ ଚ .

I A 2020, C ଲକ୍ଷ ଚ ଚ ଚ ଚ ଚ ଚ ଚ C.S.C ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ
 ଲକ୍ଷ ଚ MB5,000 ଲକ୍ଷ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ 31 D ଲକ୍ଷ 2022. I
 J 2022 ଚ A 2022, C ଲକ୍ଷ ଚ ଲକ୍ଷ NAFMII ଚ ଚ ଚ ଚ ଚ
 - ଲକ୍ଷ ଲକ୍ଷ ଚ ଚ ଚ MB6,000 ଲକ୍ଷ ଚ ଲକ୍ଷ ଲକ୍ଷ- ଲକ୍ଷ MB4,000 ଲକ୍ଷ C ଲକ୍ଷ ଚ ,
 ଲକ୍ଷ ଚ ଚ ଲକ୍ଷ ଚ ଚ ଚ ଚ ଚ ଚ .

Collateral and Pledged Assets

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : ଚ ଚ ଚ ଚ ଲକ୍ଷ
 ଚ ଲକ୍ଷ MB772 ଲକ୍ଷ (31 D ଲକ୍ଷ 2021: MB550 ଲକ୍ଷ) ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB511
 ଲକ୍ଷ (31 D ଲକ୍ଷ 2021: MB514 ଲକ୍ଷ) .

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : ଚ ଚ ଚ ଚ ଚ ଲକ୍ଷ
 MB100 ଲକ୍ଷ (31 D ଲକ୍ଷ 2021: MB69 ଲକ୍ଷ) ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ MB8 ଲକ୍ଷ (31 D ଲକ୍ଷ 2021:
 MB8 ଲକ୍ଷ) .

A ଚ 30 J 2022, ଲକ୍ଷ ଚ ଚ ଚ ଚ ଲକ୍ଷ ଲକ୍ଷ (31 D ଲକ୍ଷ 2021: MB8 ଲକ୍ଷ)
 ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ .

A ଚ 30 J 2022, G ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ : 58.67% ଚ ଚ ଚ ଚ ଚ
 A ଚ ଚ (31 D ଲକ୍ଷ 2021: 58.67% ଚ ଚ A ଚ ଚ) .

D ଚ ଚ ଚ ଚ ଚ ଚ ଚ 16 ଚ ଚ ଚ ଚ ଲକ୍ଷ .

Cash Flow

ଚ ଚ G ଲକ୍ଷ ଲକ୍ଷ ଲକ୍ଷ ଲକ୍ଷ ଲକ୍ଷ , ଚ ଚ ଚ ଚ ଚ ଚ ଚ , ଚ
 ଚ ଚ ଚ ଚ ଚ , ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ ଚ G ଚ ଚ ଚ
 ଚ ଚ G ଚ ଚ ଲକ୍ଷ () ଚ ଚ ଚ , ଚ ଚ ଚ ଚ ଚ ଚ
 ଚ 2021.

Management

D A A

								：m	C	：MB
								January – June 2022	January – June 2021	
N	1,820		1,707
N	(2,485)		(2,450)
N	2,420		770
N	1,755		27
C	6,451		7,325
C	8,274		7,248

Capital Commitments and Capital Expenditures

D ... MB2,174 m ... 4

A ... 30 J 2022, G ... MB2,544 m ... MB5,416 m ... 19

Contingent Liabilities

A ... 30 J 2022, G ...

Interest Coverage

D ... EBI DA ... 2021: 10.91 ... BN G ... MB1

RISK MANAGEMENT

Foreign Currency Exposure

The Group's foreign currency exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's foreign currency exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

Interest Rate Exposure

The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

BUSINESS REVIEW

1. The Board's Discussion and Analysis on Operations of the Group for the Reporting Period

The Group's operations for the reporting period were primarily focused on the development and construction of residential projects. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

The Group's operations for the reporting period were primarily focused on the development and construction of residential projects. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

The Group's operations for the reporting period were primarily focused on the development and construction of residential projects. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

The Group's operations for the reporting period were primarily focused on the development and construction of residential projects. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

The Group's operations for the reporting period were primarily focused on the development and construction of residential projects. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P. The Group's interest rate exposure is primarily related to its operations in the United States and the Philippines. The Group's primary operating currency is the Philippine Peso (P). The Group's assets and liabilities are primarily denominated in P.

Management

D A

	Revenue		Jan – Jun 2022		Jan – Jun 2021	MB
	Amount	Percentage of revenue (%)	Amount	Percentage of revenue (%)		
By business segment						
Medicine	14,271	67.08	12,179	72.16	17.18	
Medical devices	4,035	18.97	2,832	16.78	42.48	
Healthcare	2,917	13.71	1,843	10.92	58.27	
By geographical locations						
China	13,683	64.31	11,680	69.20	17.15	
Overseas	7,592	35.69	5,198	30.80	46.06	

Main Operational Progress of the Group during the Reporting Period

(1) The Group completed the acquisition of 100% equity of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) in December 2021. The acquisition was completed through the issuance of 1,502 million shares of the Company (RMB 150.2 billion). The acquisition price was RMB 100.00 per share, totaling RMB 150.2 billion. The acquisition price was paid in cash. The acquisition of Fosun Pharma is expected to enhance the Group's capabilities in the pharmaceutical and medical device fields and expand its market share.

The Group also completed the acquisition of 100% equity of Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) in December 2021. The acquisition was completed through the issuance of 1,502 million shares of the Company (RMB 150.2 billion). The acquisition price was RMB 100.00 per share, totaling RMB 150.2 billion. The acquisition price was paid in cash. The acquisition of Fosun Pharma is expected to enhance the Group's capabilities in the pharmaceutical and medical device fields and expand its market share.

Management

D A

Table 3 — Innovative drugs that obtained clinical approvals during the Reporting Period

No.	Name of drugs	Classification of registration	Indications
1	FCN-159	C	H
2	FCN-159	C	A
3	IN1001	C	I (I F)
4	HL 208	C	≤
5		C	E (D) (MD - B) /
6	F-1502 (-HE 2 - F) /		HE 2-
7	FKC889 ^{Note}		M (/ MCL)
8	HL 35 (-EGF -4-1BB)		≤
9	HL 53 (- IGI F)		≤
10	HL 301 (- D-L1 - IGI)		A
11	H ()		I (L-SCLC)
12	H ()+HL 07 (-EGF)+H B ()		H (HCC)
13	HL 26 (-LAG-3)+H ()		≤
14	≤ N53-67/M57-KLH (≤ M)		

Note: F K ,

Management

D ... A ...

(4) G ... D
 ...
 ... G ...
 ...
 ...
 D ... G ... INN 2.0
 ...&D ...&D ...

Segment Performance Overview

Pharmaceutical manufacturing

Performance summary

D ... MB14,271
 ... 17.18% ... MB1,890 ...
 ... 39.69% ... MB1,579 ...
 ... 25.62% (... BN ...
 ... D ... &D ...
 ... MB2,062 ... 16.04% ... &D
 ... 14.39% ...
 ... MB1,491 ... 10.41%
 ...
 D ...
 ... : 1) ... : C ... (NA C ID-19 ...
 ... H K , M... D ... 8 ...
 ... H K , M... (... 30 ...
 ... 5 11 M...
 C ... A ... M... 2022 ... H... (...) ... M... 2022,
 ... MB813 ...
 150.15%. H... L K... (...) ... MB819 ...
 ... (A) ... F ... 2022. ... K (...) ...
 ... MB360 ... ; 2) ... M... 2022, H...
 (...) ... ; 3) ...
 G ...

ମ ମା G ମା ବ ବ

: ମ C : MB

Major therapeutic area		Jan – Jun 2022	Jan – Jun 2021*	ବ ମା (%)
ମା	ବ - ମା ମା ମା (Notes 1, 7)	2,550	1,705	49.56
ମା	ବ - (Notes 2, 7)	3,629	2,656	36.63
ମା	ମା ମା ମା ମା (Notes 3, 7)	1,383	1,419	2.54
ମା	ବ ବ ବ ମା (Notes 4, 7)	1,095	1,019	7.46
ମା	ବ ମା (Notes 5, 7)	422	616	31.49
ମା	A I ବ ମା (Notes 6, 7)	633	577	9.71

Note 1: ମା ବ - ମା ମା ମା ବ 49.56%, ମା
H (ବ ମା), H L K (ମା) ବ ି K (ବ ମା ବ ବ), ବ
ମା H ି ବ (ମା) ବ A (N ବ ବ ବ H
Cା) .

Note 2: ମା ବ - ବ - - ବ 36.63%, ମା
C ମା (ମା NAC ID-19 ବ) ବ ମା ବ ବ

Note 3: ମା ମା ମା ମା ମା ବ - - ବ 2.54%, ମା
ବ ମା A ମା (ବ) ବ F K J (ବ) ବ
ମା

Note 4: ମା ବ ବ ବ ମା ବ - - ବ 7.46%, ବ ମା
ବ

Note 5: ମା ବ ମା ବ - - ବ 31.49%, ମା
ମା A D J (ବ ମା) .

Note 6: ମା A I ବ ମା ବ - - ବ 9.71%, ମା
ବ ମା

Note 7: ମା ବ - ମା ମା ମା ବ ମା : H (ବ ମା), H L K (ମା), ି K
(ବ ମା ବ ବ), H ି ବ (ମା), K ି (ବ ବ), K L (ବ
ବ), ବ H (ବ ବ), D K M (ବ ବ ବ), H D ବ (A ବ ମା), L / M ି (ମ
ମା), ବ ବ , ବ , ବ ବ ବ A (N ବ ବ ବ H
Cା) .

ମା ବ - ମା : C ମା (ମା NAC ID-19 ବ), ବ ମା ବ ବ , C ବ / B L ି
(ମା ମା), ବ ବ (E) ମା (-), M ି L (ମା ମା),
M ବ , ି D L K (ବ ମା ମା ବ ବ ବ), ବ , ବ ି L (ବ
ମା ବ ବ ମା), ବ ମା , ବ ି L / ି / E (ବ ମା ବ ବ ମା
, ବ , H D (ବମା ବ), E B (ମା ମା), ବ ମା , K D (ବ ମା
, ି K N (ବ ମା ବ) ବ ି N (ବମା ବ) .

Management

D A A

Ma (), Ba (), L (), B (), K (), L (), Ba L (H), , Fa K J ()

Ma (), K (), A (), D E (), Na () K ()

Ma (), A D J () C N ()

Ma A I (), (), ()

* () J 2021 () J 2022, () J 2021 () L D

Important events

- Progress of PD-1 inhibitor Han Si Zhuang (serplulimab injection)

I Ma 2022, () (M.S-H) () D-1 H () G () NM A () M.S-H () A 26 A 2022, H () C 18

A () NDA () (N.SCLC), () (E.S.SCLC) () () (E.S.SCLC) H () C M () D D () FDA. I () () (E.S.SCLC), () () I D M C (IDMC). () 15.4 () 10.9 () 24- () 43.1% () 7.9%

A () H () HL 07 () EGF () H B () (HCC) () C (+5-F) () (E.S.SCLC) () (F.S) () I D M C (IDMC).

Ba () C +G () H () A () 11 () H ()

Progress of CAR-T cell therapy products

Ka Da () F K a ... CA - ... J 2021, ... CA - ... B- ... (/ DLBCL) ... A ... J 2022, Ka Da ... 44 ... 100.

Ka Da () -H ... NHL) ... C Ma ... 2021. A ... C Ma ...

Ka Da () B- ... (/ LBCL) ... 12 ... A 2022. I A ... FDA ... CA - ... FDA ... LBCL. ... MA-1 ... 5- ... () ... / ... LBCL ... 42.6%, ... 5- ... C ... 64.4%. ... Ka Da, ...

I a , F K ' CA - ... FK889 ... C Ma 2022 ... MCL) a ... A ... C Ma ...

Cooperation on the joint development and exclusive commercialization of Azvudine

I J 2022, ... F ... G B ... A ... (2019- C) ... AID ... A ... C ... 25 J 2022, ... NM A ... C ID-19. ... NM A ... HI -1 ... (... AID ...) ...

9 A 2022, A ... D ... G ... C ID-19 (9 E) (《新型冠状病毒肺炎诊疗方案(第九版)》). A ... A ... G ... H ... H ... J ... H ... G ... F ... C ... A ... A ... HI ... H ... C ID-19 ...

Management

D A

- Other license-in and license-out projects

&D ... 20 ... G ... K ... B N ... App ...

L ... G ... C ... G ... App ...

(...), C ... Ma ... NM A A 2021, ... -4 (DE4) ...

App ... G ...

WT ... G ... D ... H ... I F ... 2022, ... H ... G ...

... HL 11 (... -HE 2 ... II ...) ... D ... HL 14 (... - ANKL ...) ... C ... \$538 ... \$70 ...

E ...

• Deepening of global operation

... G ... A ... 6,099 ... 16.7% ... G ...

I ... G ... 22 ... 2019- C ... 5 ... 16 ... (G) ... 21 ... 85% ... (IDN) ...

I ... A ... G ... 5 ... 800 ... B2B2C ... - ... G ... A ... K ... I ... C (IC C) ... A ... G ... (...) ... H - ... I J 2022, ... III ... G ... A ...

G ... 2022, ... F ... M ... C ID-19 ... M ... N ... C ID-19 ... N ... M ...

R&D innovation

L ... &D ... G ... &D, ... (BD) ... &D ... A ... G ... &D, ... NA, ... ADC ... &D ...

A ... 260 ... G ... 4). D ... 51 ... 26 ... G ... 6 ... 6 C ... 26 ...

Table 4 — Major pipeline drug projects

Type	Number (calculated according to indications)	Remarks
Innovative drugs	70	/
I : S	22	F , , 5. C III
B	32	F , , 6. C 8 III
L -	16	F , , 7. C 1 6 III
Biosimilars under independent development	13	F , , 8. C 2 4 III
Generic drugs	130	/
I : I	14	/
Consistency evaluation items	23	/

Note 1: G

G .

Note 2: CD19-

CD19-

CA -

FKC889

F K ,

, ,

,

,

,

,

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

 .

Table 5 — Small molecular innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period
1	A - m	FCN-338	H m a m a	a a a	a a a (.s)
2			a a B- m m	A a a	
3		FCN-159	M a m a m	a a a	
4			N m	a a a (a a m -)	
5			L - a m	A a a	
6			H m	a a a	
7		IN1001	s m	a a a	a a a (.s)
8		SAF-189	N - m a a (s1+)	a a a	A a a (.s)
9			N - m a a (ALK+)	a a a	
10		FCN-437	B a a 1L	a a a	a a a (.s)
11			B a a 2L	a a a	
12		01001	A a m	a a a	
13		FH-2001	A a m a m	a a a	
14	M a m a a m a m	FCN-342	G	a a a	
15		IN1001	I a m a (I F)	A a a	a a a (.s)
16		E -26	A a	a a a	
17		FCN-159	A m m	A a a	

Table 6 — Biopharmaceutical innovative drugs under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period	R&D progress in other countries as at the end of the Reporting Period	
1	A - m	Hx S a (ma)	M a a - (M.S-H) m	A a	A a a (note 1)	
2		Hx S a (ma)+ m a	S am - ma a (NSCLC)	a a a	a III a a (a a m -)	
3			E - a ma a (E.S.SCLC)	a a a	a III a a (a a m -)	
4			E a a am a ma (ESCC)	a III a a (note 2)		
5			N -/a a am GC	a III a a		
6			HL S a (ma)+ m a + a a	Lm - a ma a (LS.SCLC)	a III a a (a a m -)	
7		Hx S a (ma)+ Ha B a (a ma)	N - am - ma a (NSCLC)	a III a a		
8			H a a a ma (HCC)	a II a a		
9			M a a a a (mC C)	a III a a		
10		Hx S a (ma)+HL 07 (m a a -EGF ma)	m a a a a a am a ma (HN.SCC)	a II a a		
11			S am - ma a (NSCLC)	a II a a		
12		Hx S a (ma)+HL 07 (m a a -EGF ma)+Ha B a (a ma)	H a a a ma (HCC)	A a a		
13		HL 26(m a a -LAG-3 ma m a a)+Hx S a (ma)	S m a m ma	A a a		
14		HL 22(a - ma ma a -2 (HE 2) ma m a a)+Ha (a ma)	Gr a (GC)	a II a a		
15		HL 07(m a a -EGF ma m a a)	S m (-ma a , a a a a)	a I/II a a (note 3)	A (.S)	
16		HL 20(m a a -D-L1 ma m a a)	S m	A a a	a I a a (A a a)	
17		HL 26(m a a -LAG-3 ma m a a)	S m a m ma	a I a a		
18		HL 35(m a ma a -EGF a a 4-1BB a)	S m	a I a a	a I a a (A a a)	
19		HL 301(m a a -D-L1 a a - IGI a)	S m	A a a	a I a a (A a a)	
20		HL 23(m a a -CD73 ma m a a)	S m		A a a (.S)	
21		HL 53(a - IGI F)	S m a m ma	A a a		
22		HL 60(m a ma a -GA m a a)+Hx S a (ma)	A a /m a a m		(Note 4)	
23		B m	m a H ma E -H F F I	A ma	a I/II a a	
24			HL 04- (m a a -EGF ma m a a)	m a - a ma a a (AMD)	a III a a	a III a a (a a m -)

Note 1: Hx S a (ma) IND a a S a , E a .

Note 2: I Ma 2022, a III a Hx S a (ma) m a m a a . I A 2022, NDA C Ma a a a a m a a a a ma m ma . I A NM A.

Note 3: Am a I/II a a C Ma a , a a a a a , C a a m .

Note 4: I A 2022, HL 60 (m a ma a -GA m a a) m a Hx S a (ma) a m a a /m a a m a a a I a a A a a.

Table 7 — License-in innovative drugs

No.	Therapeutic area	Drug name/code	Indications	R&D progress in China as at the end of the Reporting Period
1	A - m	≤ N53-67/M57-KLH a (≤ a M)	m a a m a	A a a
2		HL 208	≤ m (m a a a a a , - m a a ,) , LCH a ECD	a II a a
3		F≤1502 (m a a - HE 2 m a m a a - m m a a F a)	N - m a a (N≤CLC)	a II a a
4			HE 2- a a a m a a a a	a I a a
5			HE 2 a a m a a m	a II a a
6		F≤1502 (m a a - HE 2 m a m a a - m m a a F a) m a m a a / m a	HE 2- a a a a	A a a
7	M a m a a m a m	a a a	I a m a (IB≤C)	a I a a
8		F a a	I a a	a III a a
9	A -	m NA a BN 162 2	a (C ID-19) a a (SA ≤C -2)	C M a a : a II a a m H K , C a : A m M a a , C a : a a a m a a m a a a , C a : a a a a m
10		m a a	E - a (D) m - a (MD - B) a m a / a a m	a I a a
11	C a m	a a	a m	NDA
12	B m	A a m a m a a a	C m m m a (I)	a III a a
13		a a a	H a m a - a a a a a (E≤ D-HD)	a III a a
14		F a a (a a a)	m a a a	a III a a
15		002 (Da m A)	M a a a a a (GL)	a III a a
16			I a a a (CD)	a III a a

Table 8 — Biosimilars under independent development

No.	Therapeutic area	Drug name/code	Indications	R&D progress in Chinese Mainland as at the end of the Reporting Period
1	A - m	HL 11 (m a a -HE 2 m a m m a a)	N a a a m BC	a III a a
2		HL 05 (m a A -EGF H m a /M C m M a A)	M a a a a (mC C)a m a a a a a a m a (HNSCC)	a I a a
3		HL 12 (m a a - EGF 2 m a II-III m a m a a)	G a a (GC), m a a - m a a (NSCLC) a m a a a a (mC C)	a I a a
4		HL 13 (m a a -C LA-4 m a m a a)	M a m a, a a m a (CC)a m a a a a (mC C)	A a a
5		HL 15 (m a a -CD38 m a m a a)	M m m a (MM)	A a a
6		H a B a (a m a)	a m a	(Note 1)
7		H a B a (a m a)	H a a a m a	(Note 2)
8	M a m a a m a m	I a	D a	NDA
9		m a	D a	A a
10		M a m a m a (50)	D a	a III a a (Note 3)
11		L a	D a	a III a a
12		HL 14 (m a a - ANKL m a m a a)	()	a III a a (a a m -)
13		H a L K a (m a)	m a A (A)	A a

Note 1: a m a a a a (NDA) H a B a (a m a) a a a m a a a a NM A J 2022.

Note 2: NDA H a B a (a m a) a a a a a m a a a NM A A 2022.

Note 3: NDA m a m a m a (50) a a NM A J 2022.

A a , a a 25 G a a a m a a a
a a a a m a (a a , a a a 9 a a a m a). F
a m a , G a a a a a m a - a m a a
m a m a m a a m a a m a , a a
m m a m a m a a m a m a m a

I ... \$175
 ... \$20.53 ...
 ... N ... E ...
 ... &D ... D ...
 ... M ...
 Jan 2022, ... &D, ...
 ... LMN ... LMN ...
 ... C ... A ... ED ... CBD+
 ... IC ... 0 ... 0.5 ... 45 ... 3 ...

Management

D A

Financing

I G
 D G 2022, C MB500
 I J 2022, C MB4,484 A 106,756,666 A
 G &D

2. Core Competitiveness Analysis

D G &D
 A. A &D G
 B. A &D, G BD &D
 C. A G 6,900 2,000 1,400

3. Major Operations in the Reporting Period

A. Analysis on Principal Operations

(1) Analysis of Changes in Relevant Items of Financial Statements

Items	Amount for the period	Amount for the corresponding period of last year	Period-on-period change (%)
(Note 1)	21,275	16,878	26.05
C (Notes 2, 7)	11,576	8,256	40.21
(Note 3)	4,166	4,211	1.07
A &D	1,715	1,505	13.95
F	1,818	1,562	16.39
(Note 4)	438	421	4.04
(Note 5)	651	1,645	60.43
	911	338	169.53
N	1,820	1,707	6.66
N	2,485	2,450	1.43
N (Note 6)	2,420	770	214.29

Note 1: F A , 5 m m M A m D

Note 2: (1) (2) (3) 45.59%, 5.49

Note 3: (1) G 19.58%, 5.37

N 3: 28

Management

D A

(2) R&D expenditure

① &D

	MB	C	MB
&D			1,818
&D			581
&D			2,399
&D		(%)	11.24
&D		(%)	14.39
&D		(%)	24.22

② D

D	&D	MB	%	MB	%	MB	%
MB2,062	MB285	16.04%					
14.39%							
&D	MB1,491	10.41%					
7.65%							
&D							

B. Segment and Regional Operations

(1) Principal Operations by Segments, Products and Regions

MB C MB

By segments	Principal operations by segments			Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
	Revenue	Cost of sales	Gross profit margin (%)			
(Note 1)	14,271	6,509	54.39	17.18	24.84	2.80
M (Note 2)	4,035	2,650	34.32	42.48	74.69	12.11
H (Note 3)	2,917	2,402	17.66	58.27	58.86	0.30

Principal operations by products

By products	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
Ma (Note 4)	2,550	493	80.67	49.56	27.06	3.43
Ma (Note 5)	3,629	1,701	53.13	36.63	43.67	2.29
Ma	1,383	289	79.10	2.54		0.53
Ma (Note 6)	1,095	706	35.53	7.46	16.50	5.00
Ma (Note 7)	422	41	90.28	31.49	6.82	2.58
Ma A I	633	476	24.80	9.71	8.43	0.88

Principal operations by geographical locations

By geographical locations	Revenue	Cost of sales	Gross profit margin (%)	Period-on-period change in revenue (%)	Period-on-period change in cost of sales (%)	Period-on-period change in gross margin
C Ma (Note 8)	13,683	6,860	49.86	17.15	27.08	3.92
C Ma (Note 9)	7,592	4,716	37.88	46.06	65.01	7.14

Note 1: (1) (2) B G C

Management

D A A

- Note 2: (1) ; (2) ; (3)
- Note 3:
- Note 4:
- Note 5:
- Note 6:
- Note 7:
- Note 8:
- Note 9:
- Note 10: F G
- Note 11: C 2021

C. Subsidiaries and Investees

(1) Operation and Results of Major Subsidiaries of the Group

① 2022 12 31 31 2021 12 31

: 100 C : MB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	197	7,053	5,037	2,542	474	410
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	452	6,115	3,292	3,818	405	359
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	N/A	8,976	7,725	1,667	481	360
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	N/A	30,644	16,874	8,064	N/A	679

Note 1: 2022 12 31 31 2021 12 31 2022 12 31 31 2021 12 31

Note 2: 2022 12 31 31 2021 12 31 2022 12 31 31 2021 12 31

② 2022 12 31 31 2021 12 31

: 100 C : MB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Net profit
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	543	8,184	2,078	1,289	252
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	285	1,842	1,049	591	164
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	50	3,334	1,926	1,033	23
2022 12 31 31 2021 12 31	2022 12 31 31 2021 12 31	N/A	3,648	2,757	1,132	133

Note 1: 2022 12 31 31 2021 12 31 2022 12 31 31 2021 12 31

Note 2: 2022 12 31 31 2021 12 31 2022 12 31 31 2021 12 31

Note 3: 2022 12 31 31 2021 12 31 2022 12 31 31 2021 12 31

Management

D A A

(2) *Operation and Results of Investee Companies whose Net Profit and Investment Income Contributing More Than 10% of the Group's Net Profit*

: m C : MB

Company name	Major business	Registered capital	Total assets	Net assets	Revenue	Operating profit	Net profit
Shanghai Fosun Pharmaceutical (Group) Co., Ltd.	Pharmaceutical	100	370,124	104,237	261,472	7,988	6,221

(3) *Acquisition and Disposal of Subsidiaries for the Reporting Period (including the Purposes and Methods of the Acquisitions and Disposals and their Effects on the Group's Overall Operation and Results)*

① A G

: m C : MB

Company name	Acquired through	Net assets (as at the end of Reporting Period)	Net profit (from date of merger/ acquisition up to the end of Reporting Period)	Date of acquisition/ merger
H E		646	8	20 Jan 2022

Note: ...

② D G

: m C : MB

Company name	Disposed through	Net assets as at date of disposal	Net profit from beginning of Reporting Period to date of disposal	Date of disposal
H E		30		3 Jan 2022
F D				21 Feb 2022
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. E		58	5	28 Feb 2022

D. Employees and Remuneration Policies

A ବ , G ବ ବ 36,604 ମ . ମ ' ମ ବ
 G ବ ମ ବ , ମ , ବ ବ ବ
 ମ .

E. Assets and Liabilities Analysis

A ବ , G ' ବ , ବ ବ ବ - ବ ବ
 ବ , ବ 30.85%, ବ ମ 27.13% ବ 31 D ମ 2021.
 A ବ , G ' ବ ବ MB169 ମ , ବ ମ
 MB1,115 ମ ବ 31 D ମ 2021. - - ବ ବ ମ
 ବ ବ ବ ବ ବ BN G ବ
 ବ ମ 2021.

4. Outlook for Operations in the Second Half of 2022

I ବ 2022, G ମ ବ
 ବ ବ ବ ବ . G ବ ମ ବ
 &D , ମ ବ ବ ବ , ବ
 ମ ବ ବ ବ ମ ବ , ବ ମ ବ
 ମ ବ ମ ମ ବ , ବ ବ ବ ମ
 ବ ବ ବ ମ ବ ବ ବ . I ବ , G ବ
 ମ ବ ବ ବ ବ ବ ମ . A ବ ମ , G
 ବ ମ ବ ବ ବ ବ ମ , ବ ମ
 ବ ବ C ID-19 ବ ବ ମ ବ ବ
 ବ ବ .

I ବ ବ , G ମ ବ
 ବ ବ ବ ବ . S ବ ବ :

Pharmaceutical Manufacturing

I ବ 2022, G ମ ମ 4IN ବ , ବ ବ &D,
 ବ ବ ବ ବ ମ
 ମ ବ ବ ବ , G W ବ
 ବ .

Management

D A

Management Discussion and Analysis

The Company's management has conducted a comprehensive review of the company's performance and financial position for the reporting period. The following information provides a detailed overview of the company's operations, financial results, and strategic initiatives.

The Company's revenue for the reporting period was primarily derived from the sale of pharmaceutical products. The total revenue was significantly higher than the previous period, reflecting the strong demand for our products and the successful execution of our marketing and sales strategies. The increase in revenue was primarily driven by the growth in sales of our core products, which have gained widespread recognition in the market.

In addition to our core products, the Company has also expanded its product portfolio through strategic acquisitions and partnerships. These initiatives have enabled us to enter new markets and diversify our product offerings, thereby enhancing our competitive advantage and long-term growth potential.

The Company's financial performance has also shown significant improvement. Our operating profit has increased substantially, indicating that our cost management and operational efficiency measures have been effective. The Company's strong financial position is supported by a robust cash flow and a healthy balance sheet, which provides a solid foundation for our future growth and expansion.

Looking ahead, the Company remains committed to its strategic vision and is focused on driving sustainable growth. We will continue to invest in research and development to bring innovative products to market, while also strengthening our marketing and sales capabilities. The Company's management team is confident in our ability to overcome challenges and achieve our long-term goals.

Medical Devices and Medical Diagnosis

The Company's Medical Devices and Medical Diagnosis segment has shown steady growth and innovation. This segment focuses on the development and production of high-quality medical devices and diagnostic equipment, which are essential for the healthcare industry.

Our Medical Devices and Medical Diagnosis products are designed to meet the needs of hospitals, clinics, and other healthcare providers. We have invested heavily in research and development to improve the performance, accuracy, and reliability of our products. Our commitment to quality and customer service has earned us a strong reputation in the market.

The Company's Medical Devices and Medical Diagnosis segment has also benefited from strategic partnerships and collaborations with leading healthcare institutions. These partnerships have provided us with valuable insights into the latest trends and requirements in the industry, enabling us to develop products that are highly competitive and meet the needs of our customers.

Looking ahead, the Company remains committed to driving innovation and growth in the Medical Devices and Medical Diagnosis segment. We will continue to invest in research and development to bring cutting-edge products to market, while also focusing on improving our manufacturing processes and customer service. The Company's management team is confident in our ability to achieve our long-term goals in this segment.

। 2022, G
 , G
 G
 &D
 &D
 G
 A&E
 G
 B
 G
 G

G
 ,
 .
 -
 .

Healthcare Services

। 2022, G
 ,
 ,
 G
 ,
 ,
 .

Management

D A

... G ...
... HIS ...
... G ...
... F ...
... EHS ...
... A ...
... G ...

... G ...
... F ...
... G ...
... C ...
... G ...
... D ...

... G ...
... MD ...
... A ...
... G ...
... I ...

B ... G ...

B. Market risks

The Company is exposed to market risks, including foreign exchange risk, interest rate risk, and commodity price risk. The Company has established a risk management system to identify, measure, and manage these risks. The Company's financial statements are prepared in RMB, and the Company's operations are primarily conducted in RMB. The Company's foreign exchange risk is primarily related to the settlement of international trade transactions. The Company uses forward exchange contracts to hedge its foreign exchange risk. The Company's interest rate risk is primarily related to the financing of its operations. The Company uses interest rate swaps to hedge its interest rate risk. The Company's commodity price risk is primarily related to the purchase of raw materials. The Company uses commodity futures to hedge its commodity price risk.

The Company is also exposed to credit risk. The Company's credit risk is primarily related to the receivables from its customers. The Company has established a credit management system to identify, measure, and manage this risk. The Company's credit risk is primarily related to the receivables from its customers. The Company has established a credit management system to identify, measure, and manage this risk.

The Company is also exposed to liquidity risk. The Company's liquidity risk is primarily related to the availability of funds to meet its obligations. The Company has established a liquidity management system to identify, measure, and manage this risk. The Company's liquidity risk is primarily related to the availability of funds to meet its obligations.

The Company is also exposed to operational risk. The Company's operational risk is primarily related to the risk of loss due to inadequate or failed internal processes, people, and systems. The Company has established an operational risk management system to identify, measure, and manage this risk.

C. Business and operating risks

(1) R&D risk of drugs

The Company is exposed to R&D risk of drugs. The R&D risk of drugs is primarily related to the risk of failure to develop new drugs. The Company has established a risk management system to identify, measure, and manage this risk. The Company's R&D risk is primarily related to the risk of failure to develop new drugs.

The Company is also exposed to regulatory risk. The regulatory risk is primarily related to the risk of changes in government regulations. The Company has established a risk management system to identify, measure, and manage this risk. The Company's regulatory risk is primarily related to the risk of changes in government regulations.

The Company is also exposed to intellectual property risk. The intellectual property risk is primarily related to the risk of infringement of patents. The Company has established a risk management system to identify, measure, and manage this risk. The Company's intellectual property risk is primarily related to the risk of infringement of patents.

The Company is also exposed to talent risk. The talent risk is primarily related to the risk of loss of key personnel. The Company has established a risk management system to identify, measure, and manage this risk. The Company's talent risk is primarily related to the risk of loss of key personnel.

Management

D A

D. Management risks

(1) Risks of internationalization

G ... A ... G ... G ...

(2) Risks arising from mergers, acquisitions and restructuring

G ... H ... G ... G ...

E. Foreign exchange risk

W ... G ... C ... G ... MB ...

F. Force majeure risks

... G ...

6. Other Events

A. Non-public issuance of A Shares

27 J 2021, C ... A ... N - I ... 12 ...

20 J 2022, C ... MB42.00 ... MB4,483,779,972.00 ... MB4,456,198,748.52 ... 22 J 2022.

27 J 2022, ... 106,756,666 A ... C ... D ...

B. Inter-bank Market Debt Financing Instruments

I M 2022, C M A M A M 2022. A A A A MB0.5 A A A A 3.50% A A M 2+2 A .

I A 2022, C M A M A A A - M M A A A A 2022. A A A A MB0.6 A A A A 2.65% A A M 120 A .

C. The Public Issuance of Corporate Bonds to Qualified Investors

I F A 2022, A A 2022 ' M A A A (2) A A F A A A A (G) C ., L .* 2018 (18 F A M A 03) (上海復星醫藥(集團)股份有限公司2018年公開發行公司債券(第二期)(品種二)(18復藥03), A A A A C M A M A M A A MB8.95 M A A A A A M 30 N M 2021 15 F A 2022 (A) .

I M 2022, A M A M A MB1,091.95 M A A A A I A C A B (F A) A A F A A A A (G) C ., L .* A I 2017 (17 F A M A 01) (上海復星醫藥(集團)股份有限公司2017年公開發行公司債券(面向合格投資者)(第一期)(17復藥01) A M A A A .

A 2022, A A, D B A C D, M. D, B A C D.

SUPERVISORS

A, C . . . :
M. (任倩) (Chairman)
M.C.G (曹根興)
M.G (管一民)

A C J 2022, M.
C C 1J 2022. A
1J 2022, M.C.G M.G

CHANGE OF INFORMATION OF DIRECTORS AND SUPERVISORS

M.C D II H L
Jan 2022 B F C., L.* (北京三元食品股份有限公司) (600429), E 20 A 2022.

M. G D C C
A C L.* (重慶長安汽車股份有限公司) (000625), 15 J 2022.

M. G G H C L.* (綠地控
股集團股份有限公司) (600606), 16 F
2022, J N A C., L.* (江蘇農華智慧農業科技股份
有限公司) (000816), 19 A 2022, A
1 A 2022. (G) C., L.* (上海錦江航運(集團)股份有限公司)

D () () 13.51(2) H
K L.

Statutory D

SHARE INCENTIVE SCHEMES

Gland Pharma Share Option Incentive Scheme

As at 25 J 2019, the Company has granted 1,704,440 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 1 year. The share options are subject to the terms and conditions of the Gland Pharma Share Option Incentive Scheme.

As at 17 Mv 2020, the Company has granted 154,950 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 1 year. The share options are subject to the terms and conditions of the Gland Pharma Share Option Incentive Scheme.

As at 27 J 2019, the Company has granted 103 share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 1 year. The share options are subject to the terms and conditions of the Gland Pharma Share Option Incentive Scheme.

As at 17 Mv 2020, the Company has granted (1) share options to employees under the Gland Pharma Share Option Incentive Scheme. The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 1 year. The share options are subject to the terms and conditions of the Gland Pharma Share Option Incentive Scheme.

Participant	Date of Grant (dd-mm-yyyy)	Vesting Period (dd-mm-yyyy) ⁽¹⁾	Option share ⁽¹⁾	Exercise period (dd-mm-yyyy) ⁽¹⁾	Outstanding options as at 1 January 2022	Exercise price per share	Granted	Exercised	Forfeited or	Outstanding options as at 30 June 2022
							during the Reporting Period	during the Reporting Period ⁽²⁾	lapsed during the Reporting Period	
Emp v v	27 6 2019	27 6 2019 - 19 11 2020	40%	20 11 2020 - 26 6 2029	455,500	IN 542	0	353,200	0	102,300
		27 6 2019 - 30 3 2021	30%	31 3 2021 - 26 6 2029						
		27 6 2019 - 30 3 2022	30%	31 3 2022 - 26 6 2029						

Notes:

(1) The exercise price of the share options is IN 542 per share. The vesting period of the share options is 3 years from the date of grant, with a cliff vesting period of 1 year. The share options are subject to the terms and conditions of the Gland Pharma Share Option Incentive Scheme.

(2) The exercise price of the share options is IN 3,219.12 per share.

Fosun Health Share Option Scheme

1J 2022. F H v S v S m v v v v v m
 v F H v G ' v v m v m v F H v
 G ' - m m .

v v v v v v v v m v v
 F H v S v S m v MB380,435,000 v v F H v , v
 10% v v F H v v v F H v S v S m v
 v v v ' m F H v . v v v F
 H v S v S m MB1.0 v . F v () v v v v ,
 v 50% v v v (. . MB1 v v) F H v (v) v
 m v v v F H v v v v v (. .
 MB1 v v) F H v v m v , v v v v
 v v v v . F H v S v S m v v v
 10 v m v F H v S v S m v v v ' m
 F H v .
 D , F H v v F H v S v S m .

Statutory

D

DIRECTORS', SUPERVISORS' AND CHIEF EXECUTIVE'S INTERESTS AND SHORT POSITIONS IN SHARES, UNDERLYING SHARES AND DEBENTURES

As at 30 June 2022, the interests and short positions of the directors, supervisors and chief executive of the Company in the shares, underlying shares and debentures of the Company and any other related entities, and their family members, and any other related entities, as required to be disclosed to the Company by the Securities and Futures Commission and the Stock Exchange of Hong Kong, are as follows:

(1) Long positions in the Shares, underlying Shares and debentures of the Company

Name of Directors/ chief executive	Capacity	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class
---------------------------------------	----------	-----------------	---------------------------------	---

INTERESTS AND SHORT POSITIONS OF SUBSTANTIAL SHAREHOLDERS IN SHARES AND UNDERLYING SHARES

As at 30 June 2022, the following table shows the interests and short positions of substantial shareholders in the Shares and underlying Shares of the Company as required by section 336(2) of the Companies Act, 2008. The information is given in respect of the period from 1 January 2022 to 30 June 2022.

Name of Shareholders	Nature of interest	Class of Shares	Number of Shares ⁽¹⁾	Approximate percentage of Shares in relevant class of Shares
F H	B	H	71,533,500 (L)	12.96%
	B	A	938,095,290 (L)	46.65%
F I	B	H	6,000,000 (L)	1.09%
	I	H	71,533,500 (L) ⁽²⁾	12.96%
F H	I	A	938,095,290 (L) ⁽⁴⁾	46.65%
	I	H	77,533,500 (L) ⁽³⁾	14.05%
F I	I	A	938,095,290 (L) ⁽⁴⁾	46.65%
	I	H	77,533,500 (L) ⁽³⁾	14.05%
M.G G	I	A	938,095,290 (L) ⁽⁴⁾	46.65%
	I	H	77,533,500 (L) ⁽³⁾	14.05%
B	I	A	938,095,290 (L) ⁽⁴⁾	46.65%
	B	A	114,075 (L)	0.01%
B	I	H	29,489,216 (L)	5.34%
	I	H	401,000 (S)	0.07%

Notes:

(1) (L) Long position; (S) Short position

(2) The interest of F H in the Shares is held on behalf of F I, which is a wholly owned subsidiary of F H.

(3) The interest of F H in the Shares is held on behalf of F I, which is a wholly owned subsidiary of F H. F I also holds 6,000,000 Shares of the Company. F I is a wholly owned subsidiary of F H. F H holds 72.45% of the Shares of the Company. F H also holds 85.29% of the Shares of the Company. M.G G also holds 14.05% of the Shares of the Company.

(4) The interest of F H in the Shares is held on behalf of F I, which is a wholly owned subsidiary of F H. F I also holds 6,000,000 Shares of the Company. F I is a wholly owned subsidiary of F H. F H holds 72.45% of the Shares of the Company. F H also holds 85.29% of the Shares of the Company. M.G G also holds 14.05% of the Shares of the Company.

Statutory D

DIRECTORS' AND SUPERVISORS' RIGHTS TO ACQUIRE SHARES OR DEBENTURES

Section 256, Companies Act, 2013 provides that a company shall not make any allotment of shares or debentures to any person who is a director or supervisor of the company, unless the company has first obtained the approval of the shareholders in general meeting.

MODEL CODE FOR SECURITIES TRANSACTIONS

The Model Code for Securities Transactions for Directors and Supervisors is set out in Schedule III of the Companies Act, 2013. It provides guidelines for the securities transactions of directors and supervisors of a company.

COMPLIANCE WITH THE CG CODE

The Companies (Directors and Key Managerial Personnel) Regulations, 2014 provide that every company shall have a Code of Conduct for its directors and key managerial personnel. The Code of Conduct shall be in accordance with the provisions of the Regulations.

The Code of Conduct shall be approved by the shareholders in general meeting. The Code of Conduct shall be available to all directors and key managerial personnel of the company.

Section 2.1 of the Code of Conduct (CGC) provides that a director or key managerial personnel shall not trade in the securities of the company or any other company in which the company has a substantial interest, during the period of the Code of Conduct. The Code of Conduct shall be applicable to all directors and key managerial personnel of the company.

Section 2.1 of the Code of Conduct (CGC) provides that a director or key managerial personnel shall not trade in the securities of the company or any other company in which the company has a substantial interest, during the period of the Code of Conduct.

REVIEW OF INTERIM RESULTS AND INTERIM REPORT BY THE AUDIT COMMITTEE

As at the end of the interim period, the interim financial statements of the Company are prepared in accordance with the applicable accounting standards, and the interim financial statements of the Company are true and fair.

The interim financial statements of the Company are prepared in accordance with the applicable accounting standards, and the interim financial statements of the Company are true and fair.

The interim financial statements of the Company are prepared in accordance with the applicable accounting standards, and the interim financial statements of the Company are true and fair.

Wu Yifang
Chairman

29 A 2022

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

L

For the six months ended 30 June 2022

		For the six months ended 30 June	
		2022	2021
	Notes	RMB'000 (Unaudited)	MB'000 () ()
REVENUE	5	21,274,606	16,877,537
C		(11,575,661)	(8,256,422)
G		9,698,945	8,621,115
S	6	183,645	141,714
A		(4,166,397)	(4,211,431)
A		(1,715,275)	(1,505,057)
I		(1,818,335)	(1,561,885)
I	7	(22,860)	(14,804)
F		651,104	1,645,255
S		(911,494)	(338,367)
J	8	118,416	116,605
A		(438,187)	(420,725)
J		(99,564)	(93,817)
A		898,583	925,626
PROFIT BEFORE TAX	9	2,378,581	3,304,229
I	10	(509,086)	(550,647)
PROFIT FOR THE PERIOD		1,869,495	2,753,582
A		1,553,504	2,482,373
N		315,991	271,209
		1,869,495	2,753,582
EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT	12		
B		RMB0.60 Yuan	MB0.97
F			
D		RMB0.60 Yuan	MB0.97
F			

Interim Condensed Consolidated

Sam C m | m

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
PROFIT FOR THE PERIOD	1,869,495	2,753,582
OTHER COMPREHENSIVE INCOME		
E a : S a m () a m a a S a m ()/ m a a	115,920 48 (71,933)	(201,712) (804) 54,912
Net other comprehensive income/(loss) that may be reclassified to profit or loss in subsequent periods	44,035	(147,604)
E : C a a a I m a	(8,121) 1,218	5,200 (780)
	(6,903)	4,420
S a m m a a	—	10,725
Net other comprehensive (loss)/income that will not be reclassified to profit or loss in subsequent periods	(6,903)	15,145
OTHER COMPREHENSIVE INCOME/(LOSS) FOR THE PERIOD, NET OF TAX	37,132	(132,459)
TOTAL COMPREHENSIVE INCOME FOR THE PERIOD	1,906,627	2,621,123
A a :	1,622,372	2,385,072
N -	284,255	236,051
	1,906,627	2,621,123

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 December 2021 MB'000 (Audited)
NON-CURRENT ASSETS			
Property, plant and equipment	13	13,890,670	13,011,818
Intangible assets		2,634,025	2,569,796
Goodwill		9,933,642	9,399,987
Investments in associates		12,555,179	11,610,712
Investments in subsidiaries		299,227	282,837
Equity instruments in subsidiaries		22,835,121	22,343,990
Financial assets at fair value through profit or loss		21,795	29,916
Derivatives		1,634,964	1,206,489
Other non-current assets		320,388	265,589
		77,469	77,395
		2,414,451	2,013,740
		66,616,931	62,812,269
CURRENT ASSETS			
Accounts receivable	14	6,143,790	5,472,315
Prepayments, deposits and other receivables		7,292,310	6,045,460
Financial assets at fair value through profit or loss		3,038,152	3,466,043
Derivatives		2,386,620	4,241,069
Other current assets		554,168	427,884
Contract assets		12,258,061	10,308,157
		31,673,101	29,960,928
Accounts payable		463,705	463,705
		32,136,806	30,424,633
CURRENT LIABILITIES			
Accounts payable	15	5,707,081	5,063,661
Contract liabilities		6,621,586	7,020,048
Other current liabilities	16	17,569,068	15,460,243
Financial liabilities at fair value through profit or loss		170,838	141,496
Contract liabilities		1,207,096	1,150,274
Other current liabilities		691,691	474,223
		31,967,360	29,309,945
NET CURRENT ASSETS		169,446	1,114,688
TOTAL ASSETS LESS CURRENT LIABILITIES		66,786,377	63,926,957

Interim Condensed Consolidated

Sam Fara

30 June 2022

	Notes	30 June 2022 RMB'000 (Unaudited)	31 Dec 2021 MB'000 (A)
NON-CURRENT LIABILITIES			
1 - 3 3 3			
	16	12,033,558	9,049,069
L 3 3		687,975	648,360
D 3 3		3,273,451	3,129,746
C 3 3		176,007	239,011
D 3 3		520,014	512,806
		2,412,002	2,029,287
3 - 3		19,103,007	15,608,279
Net assets		47,683,370	48,318,678
EQUITY			
Equity attributable to owners of the parent			
1 3 3 3		2,562,899	2,562,899
		35,585,198	36,572,163
		38,148,097	39,135,062
Non-controlling interests		9,535,273	9,183,616
Total equity		47,683,370	48,318,678

Interim Condensed Consolidated

Statement of Financial Position

For the period ended 30 June 2022

Attributable to owners of the parent

	Share capital	Share premium	Fair value reserve	Statutory surplus reserve	Other reserve	Exchange fluctuation reserve	Retained profits	Total	Non-controlling interests	Total equity
	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000	RMB'000
A 1 Jūnī 2022 (A)	2,562,899	11,385,162*	203,703*	2,826,306*	2,784,724*	(1,457,965)*	20,830,233*	39,135,062	9,183,616	48,318,678
—	—	—	—	—	—	—	1,553,504	1,553,504	315,991	1,869,495
—	—	(6,471)	—	—	—	—	(6,471)	(6,471)	(432)	(6,903)
—	—	(71,885)	—	—	—	—	(71,885)	(71,885)	—	(71,885)
—	—	—	—	—	—	147,224	—	147,224	(31,304)	115,920
—	—	(78,356)	—	—	—	147,224	1,553,504	1,622,372	284,255	1,906,627
A	—	—	—	—	(1,150,544)	—	—	(1,150,544)	(74,382)	(1,224,926)
A	—	—	—	—	—	—	—	—	196,369	196,369
E	—	—	—	—	—	—	—	—	1,360	1,360
D	—	—	—	—	—	4,922	—	4,922	11,421	16,343
D	—	—	—	—	(9,435)	—	—	(9,435)	—	(9,435)
C	—	—	—	—	—	—	—	—	23,151	23,151
D	—	—	—	—	—	—	—	—	(141,048)	(141,048)
D	—	—	—	—	—	—	—	—	(15,420)	(15,420)
E	—	—	—	—	—	—	—	—	61,756	61,756
F	—	—	—	—	—	—	—	—	—	—
—	—	—	—	—	(28,381)	—	—	(28,381)	2,020	(26,361)
—	—	—	—	—	—	—	—	—	—	—
—	—	—	—	—	9,566	—	—	9,566	2,175	11,741
F	—	—	—	—	—	—	(1,435,465)	(1,435,465)	—	(1,435,465)
—	—	—	—	—	—	—	—	—	—	—
—	—	(33,142)	—	—	—	—	33,142	—	—	—
A 30 Jūnī 2022 (A)	2,562,899	11,385,162*	92,205*	2,826,306*	1,610,852*	(1,310,741)*	20,981,414*	38,148,097	9,535,273	47,683,370

* 2021 gada beigās: MB 35,585,198,000 (31. decembris 2021); MB 36,572,163,000 (31. decembris 2021)

Interim Condensed Consolidated

Σ α μ C α E

For the six months ended 30 June 2022

	Σ α		C α		E		N			
	α α	μ μ	α α	μ μ	α α	μ μ	α α	μ μ	α α	
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	
A 1 J α 2021 (A)	2,562,899	11,385,162*	139,710*	2,728,604*	3,888,329*	(1,061,719)*	17,295,662*	36,938,647	8,988,749	45,927,396
							2,482,373	2,482,373	271,209	2,753,582
C α α α μ α α				2,698				2,698	1,722	4,420
Σ α μ μ μ				64,833				64,833		64,833
E α α α α						(164,832)		(164,832)	(36,880)	(201,712)
α μ μ μ			67,531			(164,832)	2,482,373	2,385,072	236,051	2,621,123
A -					(460,551)			(460,551)	(67,129)	(527,680)
A α α									9,600	9,600
E α μ α α									169,710	169,710
D μ α α α α						9,104		9,104	37,128	46,232
D α α α					(17,557)			(17,557)		(17,557)
C α α μ - α									35,420	35,420
D α - α									(65,723)	(65,723)
D α α α				(2,449)			2,449		(175,821)	(175,821)
E - α - α α μ									58,179	58,179
F α α μ α μ										
α - α										
Σ α α α μ					6,469			6,469	(4,166)	2,303
μ α α α α					45,862			45,862	13,540	59,402
F α 2020 α α							(1,102,997)	(1,102,997)		(1,102,997)
A 30 J 2021 (α)	2,562,899	11,385,162*	207,241*	2,726,155*	3,471,656	(1,226,551)*	18,677,487*	37,804,049	9,235,538	47,039,587

* α α μ α MB35,241,150,000 (31 D μ 2020: MB34,375,748,000) α α μ

Interim Condensed Consolidated

Shanghai Fosun Pharmaceutical (Group) Co., Ltd.

For the six months ended 30 June 2022

		For the six months ended	
		30 June	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	()
	Notes		
Cash and cash equivalents		2,221,854	2,094,337
Less: Cash equivalents		(401,483)	(387,696)
Net cash and cash equivalents		1,820,371	1,706,641
CASH FLOWS FROM INVESTING ACTIVITIES			
Acquisition of intangible assets		(2,595,334)	(2,286,070)
Acquisition of subsidiaries	17	(459,451)	(21,391)
Disposal of subsidiaries		(239,719)	(100,172)
Disposal of equity investments		(252,071)	(191,752)
Disposal of property, plant and equipment		6,581	537,242
Disposal of financial assets		1,256,217	80,764
Disposal of other financial assets	18	704,493	237,609
Disposal of investment properties		55,719	61,154
Disposal of other non-current assets		32,175	8,009
Disposal of other non-current assets		103,686	18,421
Disposal of other non-current assets		(25,000)	(12,392)
Disposal of other non-current assets		(1,310,390)	(819,125)
Disposal of other non-current assets		161,366	6,509
Disposal of other non-current assets		76,573	31,450
Net cash used in investing activities		(2,485,155)	(2,449,744)

Interim Condensed Consolidated

Sum Ca F

For the six months ended 30 June 2022

	For the six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
CASH FLOWS FROM FINANCING ACTIVITIES		
N	17,847,543	14,234,577
	(12,918,555)	(12,719,442)
I	(448,224)	(419,549)
	(88,200)	(68,914)
Ca	41,508	251,362
D	(1,335,223)	
D	(74,686)	(69,024)
A	(1,088,182)	(530,770)
B	411,520	
	72,683	91,429
N	2,420,184	769,669
N	1,755,400	26,566
Ca	6,450,650	7,324,881
E	68,077	(103,270)
Ca	8,274,127	7,248,177
Analysis of balances of cash and cash equivalents:		
Ca	12,258,061	10,489,133
L	(3,983,934)	(3,240,956)
Ca	8,274,127	7,248,177

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

1. CORPORATE AND GROUP INFORMATION

The Company is a public company incorporated in the Cayman Islands. The Company was established on 31 March 1995. The Company's principal place of business is in Hong Kong. The Company is a subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (the "Parent Company"). The Parent Company is a public company incorporated in the People's Republic of China. The Parent Company's principal place of business is in Shanghai, China. The Parent Company is listed on the Shanghai Stock Exchange. The Company is a subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (the "Parent Company"). The Parent Company is a public company incorporated in the People's Republic of China. The Parent Company's principal place of business is in Shanghai, China. The Parent Company is listed on the Shanghai Stock Exchange.

The Company is a subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (the "Parent Company"). The Parent Company is a public company incorporated in the People's Republic of China. The Parent Company's principal place of business is in Shanghai, China. The Parent Company is listed on the Shanghai Stock Exchange. The Company is a subsidiary of Fosun Pharmaceutical (Group) Co., Ltd. (the "Parent Company"). The Parent Company is a public company incorporated in the People's Republic of China. The Parent Company's principal place of business is in Shanghai, China. The Parent Company is listed on the Shanghai Stock Exchange.

2. BASIS OF PREPARATION

The financial statements are prepared in accordance with the HKAS 34 Interim Financial Reporting. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis.

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES

The financial statements are prepared in accordance with the HKAS 34 Interim Financial Reporting. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis. The financial statements are prepared on a going concern basis.

Amended HKF 33 Reference to the Conceptual Framework
 Amended HKAS 16 Property, Plant and Equipment: Proceeds from Disposal of Non-current Assets

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

- (a) Application of HKF 33 *Framework for the Preparation and Presentation of Financial Statements* and HKF 37 *Conceptual Framework for Financial Reporting* (2018)
- HKF 33 and HKF 37 were issued in 2018. The Group has adopted these standards from 1 July 2022. The adoption of HKF 33 and HKF 37 does not have any material impact on the Group's financial statements.
- (b) Application of HKAS 16 *Property, Plant and Equipment* (2019)
- HKAS 16 was issued in 2019. The Group has adopted this standard from 1 July 2021. The adoption of HKAS 16 does not have any material impact on the Group's financial statements.
- (c) Application of HKAS 37 *Provisions, Contingent Liabilities and Contingent Assets* (2019)
- HKAS 37 was issued in 2019. The Group has adopted this standard from 1 July 2022. The adoption of HKAS 37 does not have any material impact on the Group's financial statements.
- (d) Application of HKF 1, HKF 9, IAS 1 and EAS 1
- HKF 1, HKF 9, IAS 1 and EAS 1 were issued in 2018-2020. The Group has adopted these standards from 1 July 2022. The adoption of HKF 1, HKF 9, IAS 1 and EAS 1 does not have any material impact on the Group's financial statements.
- HKF 9 *Financial Instruments*: The Group has adopted HKF 9 from 1 July 2022. The adoption of HKF 9 does not have any material impact on the Group's financial statements.

Notes to Interim Condensed Consolidated

F o s u n | P h a r m a

30 J u n e 2022

3. CHANGES IN ACCOUNTING POLICIES AND DISCLOSURES (Continued)

As at 30 June 2022, the Group has adopted the following new accounting policies and disclosures:

(a) **Leases**

HKF 16 Leases: The Group has adopted HKF 16, which is effective from 1 January 2022. The Group has elected to apply the modified retrospective method of transition. The Group has not restated comparative information for the period ended 30 June 2021. The Group has applied HKF 16 to all leases with a term of 12 months or more, and all leases with a term of 12 months or more that include a purchase option or other features that would lead to the lease being classified as a finance lease.

4. OPERATING SEGMENT INFORMATION

The Group's operating segments are defined as components of the Group that are engaged in providing products or services, and for which discrete financial information is available and is reviewed regularly by the Group's management to make decisions about resources to be allocated and to assess performance.

(a) **Operating segments**

The Group's operating segments are as follows:

(i) **Pharmaceuticals**

The Pharmaceuticals segment is engaged in the research, development, production and distribution of pharmaceutical products.

(ii) **Medical devices**

The Medical devices segment is engaged in the research, development, production and distribution of medical devices.

(iii) **Others**

The Others segment is engaged in the research, development, production and distribution of other products.

(iv) **Corporate**

The Corporate segment is engaged in the provision of corporate services.

The Group's operating segments are as follows:

(i) **Pharmaceuticals**

The Pharmaceuticals segment is engaged in the research, development, production and distribution of pharmaceutical products. The segment's revenue is derived from the sale of pharmaceutical products. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

(ii) **Medical devices**

The Medical devices segment is engaged in the research, development, production and distribution of medical devices. The segment's revenue is derived from the sale of medical devices. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

(iii) **Others**

The Others segment is engaged in the research, development, production and distribution of other products. The segment's revenue is derived from the sale of other products. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

(iv) **Corporate**

The Corporate segment is engaged in the provision of corporate services. The segment's revenue is derived from the provision of corporate services. The segment's expenses include administrative expenses.

The Group's operating segments are as follows:

(i) **Pharmaceuticals**

The Pharmaceuticals segment is engaged in the research, development, production and distribution of pharmaceutical products. The segment's revenue is derived from the sale of pharmaceutical products. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

(ii) **Medical devices**

The Medical devices segment is engaged in the research, development, production and distribution of medical devices. The segment's revenue is derived from the sale of medical devices. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

(iii) **Others**

The Others segment is engaged in the research, development, production and distribution of other products. The segment's revenue is derived from the sale of other products. The segment's expenses include research and development, production, distribution, sales and marketing, and administrative expenses.

Notes to Interim Condensed Consolidated

F a a I m a

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2022 (unaudited)

	Pharmaceutical manufacturing RMB'000	Medical devices and medical diagnosis RMB'000	Healthcare Service RMB'000	Pharmaceutical distribution and retail RMB'000	Other business operations RMB'000	Eliminations RMB'000	Total RMB'000
Segment revenue:							
Σ a a m	14,270,930	4,034,954	2,916,662	—	52,060	—	21,274,606
l m a	140,363	214,035	43,313	—	9,334	(407,045)	—
a	14,411,293	4,248,989	2,959,975	—	61,394	(407,045)	21,274,606
Segment results*							
m	1,889,837	439,669	(386,703)	—	41,388	(20,930)	1,963,261
a	103,862	11,334	15,396	—	11,013	—	141,605
l m	302,498	301,515	47,933	—	—	—	651,946
F a	83,261	7,596	12,901	—	110	(5,711)	98,157
	(105,897)	(14,518)	(89,415)	—	(4,325)	49,853	(164,302)
	(229,699)	(28,089)	(19,820)	—	14,642	305	(262,661)
Σ a a :							
J	(96,979)	—	—	—	(2,585)	—	(99,564)
A a	14,208	93,494	(16,446)	919,864	(112,537)	—	898,583
a a m, m,							
a, a, a							(848,444)
/() a	1,961,091	811,001	(436,154)	919,864	(52,294)	23,517	2,378,581
a	(382,366)	(111,764)	(5,670)	—	(23)	—	(499,823)
a a a							(9,263)
/()	1,578,725	699,237	(441,824)	919,864	(52,317)	23,517	1,869,495
Segment assets:	51,748,370	10,007,104	11,108,724	16,774,252	5,021,141	(2,539,162)	92,120,429
l :							
Investments in joint ventures	290,610	—	832	—	7,785	—	299,227
Investments in associates	1,318,013	1,250,089	893,241	16,774,252	2,599,526	—	22,835,121
a a a							6,633,308
a a							98,753,737
Segment liabilities:	22,453,057	3,539,092	5,408,677	—	1,497,902	(15,682,906)	17,215,822
a a a							33,854,545
a a							51,070,367
Other segment information:							
D a a a m a	722,087	115,279	206,588	—	20,372	—	1,064,326
l m a m a m							
	65,473	20,319	11,628	—	—	—	97,420
C a a **	1,800,755	155,846	196,281	—	21,210	—	2,174,092

* Σ m a a a m a, a, a, a m a a a a

** C a a a m, a a a a a a a m

Note: a m a a m a m a a a B N a a m

Notes to Interim Condensed Consolidated Financial Statements

30 June 2022

4. OPERATING SEGMENT INFORMATION (Continued)

Six months ended 30 June 2021 (unaudited)

	Revenue	Cost of sales	Operating expenses	Other income	Other expenses	Share of results of associates	
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
Segment revenue:							
Pharmaceutical	12,179,257	2,832,211	1,843,434	22,635			16,877,537
Others	13,233	17,779	20,501	12,639	(64,152)		
	12,192,490	2,849,990	1,863,935	35,274	(64,152)		16,877,537
Segment results*							
Pharmaceutical	1,352,891	434,099	(19,393)	9,266	(23,352)		1,753,511
Others	102,012	14,123	15,428	7,430			138,993
Investment	201,990	2,283	87,416	262,270	(111,725)		442,234
Finance	85,180	16,516	14,508	1,698	(14,636)		103,266
Others	(80,436)	(13,698)	(25,545)	(5,312)	21,894		(103,097)
	(35,582)	(34,764)	(12,181)	(258,830)			(341,357)
Share of results of associates:							
Joint ventures	(93,805)				(12)		(93,817)
Associates	35,707	90,143	(28,178)	896,991	(69,037)		925,626
Share of results of associates							478,870
/()	1,567,957	508,702	32,055	896,991	(52,527)	(127,819)	3,304,229
	(311,399)	(54,486)	(47,288)		(2)		(413,175)
							(137,472)
/()	1,256,558	454,216	(15,233)	896,991	(52,529)	(127,819)	2,753,582
Segment assets:	46,659,269	8,322,272	9,898,810	15,355,639	4,458,138	(2,668,056)	82,026,072
Investments in joint ventures	342,929				6,148		349,077
Investments in associates	2,273,758	555,078	1,589,874	15,355,639	2,673,511		22,447,860
							6,396,412
							88,422,484
Segment liabilities:	17,422,127	2,202,799	2,555,456		710,137	(10,426,621)	12,463,898
							28,918,999
							41,382,897
Other segment information:							
Depreciation and amortization	643,074	123,971	157,392		21,010		945,447
Impairment losses	(1,288)	25,438	7,872		190,114		222,136
Carrying amount of non-current assets	1,323,129	137,508	477,910		102,565		2,041,112

* Segment results are calculated based on the accounting policies of the respective operating segments. The accounting policies of the operating segments are consistent with the accounting policies of the Group.

** Carrying amount of non-current assets is calculated based on the carrying amount of non-current assets less accumulated depreciation and amortization.

Note: Revenue is measured in million RMB, and other amounts are in million RMB.

Notes to Interim Condensed Consolidated

F a a l m a

30 June 2022

5. REVENUE

A a a a :

				For the six months ended	
				30 June	
				2022	2021
				RMB'000	MB'000
				(Unaudited)	(a)
	m	a	m	21,258,760	16,864,028
	m				
G	a	m		15,846	13,509
				21,274,606	16,877,537

Disaggregated revenue information for revenue from contracts with customer

For the six months ended 30 June 2022 (unaudited)

Segments				Pharmaceutical	Medical	Healthcare	Other business	Total
				manufacturing	devices			
				RMB'000	and medical	RMB'000	RMB'000	RMB'000
					diagnosis			
					RMB'000			
Types of goods or services								
	Sa			13,844,207	3,915,452	441,291	—	18,200,950
				418,473	89,828	2,472,638	41,175	3,022,114
	Sa	ma	a	6,625	29,071	—	—	35,696
				14,269,305	4,034,351	2,913,929	41,175	21,258,760
Geographical markets								
	Ma	a	C	9,253,783	1,460,631	2,913,290	39,753	13,667,457
				5,015,522	2,573,720	639	1,422	7,591,303
				14,269,305	4,034,351	2,913,929	41,175	21,258,760
Timing of revenue recognition								
	G	a	a	13,850,832	3,944,523	441,291	—	18,236,646
				276,437	33,096	2,472,638	41,175	2,823,346
				142,036	56,732	—	—	198,768
				14,269,305	4,034,351	2,913,929	41,175	21,258,760

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

5. REVENUE (Continued)

Disaggregated revenue information for revenue from contracts with customers (Continued)

For the six months ended 30 June 2021 (unaudited)

S m	M a		H a a		a	
	a m a a	a m a	a	a	a	a
	MB'000	MB'000	MB'000	MB'000	MB'000	MB'000
Types of goods or services						
a	11,733,205	2,742,001	37,479			14,512,685
	414,422	76,259	1,804,041	11,459		2,306,181
a m a	30,599	13,951	612			45,162
a m a m	12,178,226	2,832,211	1,842,132	11,459		16,864,028
Geographical markets						
M a a C a	8,474,661	1,339,179	1,842,132	10,040		11,666,012
a a	3,703,565	1,493,032		1,419		5,198,016
a m a m	12,178,226	2,832,211	1,842,132	11,459		16,864,028
Timing of revenue recognition						
G a a a m	11,763,804	2,755,952	38,091			14,557,847
S a a a m	297,157	13,239	1,804,041	11,459		2,125,896
S a m	117,265	63,020				180,285
a m a m	12,178,226	2,832,211	1,842,132	11,459		16,864,028

Notes to Interim Condensed Consolidated

F a a | m

30 June 2022

6. OTHER INCOME

		For the six months ended 30 June	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	()
D	m m a a a a a a a		
	m a a a a	36,451	8,009
G	m a	147,045	132,660
		149	1,045
		183,645	141,714

7. OTHER GAINS

		For the six months ended 30 June	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	()
Ga	a m a a	186,594	279,501
Fa	a a a a a a a	—	1,230,308
Ga	a a	382,978	78,995
		81,532	56,451
		651,104	1,645,255

8. FINANCE COSTS

		For the six months ended 30 June	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	()
I	a a	444,244	413,098
I	a a	22,647	14,841
L : I	a a	(28,704)	(7,214)
		438,187	420,725

Notes to Interim Condensed Consolidated

F a n a l r e p o r t

30 J u n e 2022

9. PROFIT BEFORE TAX

G e n e r a l a n d o t h e r b u s i n e s s ():

	For the six months ended	
	2022 RMB'000 (Unaudited)	2021 MB'000 () ()
C o n t r i b u t i o n f r o m o p e r a t i n g a c t i v i t i e s	9,672,149	6,579,164
C o n t r i b u t i o n f r o m f i n a n c i n g a c t i v i t i e s	1,903,512	1,677,258
U n d e r l i n e	4,106,468	3,070,335
D e p r e c i a t i o n a n d a m o r t i z a t i o n	261,459	180,142
A m o u n t o f i n v e n t o r y i m p a i r m e n t	153,680	101,061
U n d e r l i n e	33,725	39,619
U n d e r l i n e	4,555,332	3,391,157
U n d e r l i n e	1,722,222	1,494,528
L o s s o n g o o d w i l l & D	(50,780)	(27,604)
U n d e r l i n e	29,708	21,673
D e p r e c i a t i o n a n d a m o r t i z a t i o n	609,401	564,429
D e p r e c i a t i o n a n d a m o r t i z a t i o n	114,947	101,351
A m o u n t o f i n v e n t o r y i m p a i r m e n t	339,978	279,667
I m p a i r m e n t o f f i n a n c i a l a s s e t s	29,341	16,953
I m p a i r m e n t o f i n v e n t o r y	20,601	15,022
I n t e r e s t i n c o n t r a c t s	2,259	(218)
I m p a i r m e n t o f f i n a n c i a l a s s e t s	45,224	—
I m p a i r m e n t o f i n v e n t o r y	—	190,379
F a v o r a b l e e x c h a n g e d i f f e r e n c e	640,805	(1,230,308)
F a v o r a b l e e x c h a n g e d i f f e r e n c e	(72,842)	(41,939)
L o s s o n g o o d w i l l & D	2,306	10,166
U n d e r l i n e	100,671	

* G e n e r a l a n d o t h e r b u s i n e s s ()

Notes to Interim Condensed Consolidated

F a n a l 2022

30 June 2022

10. INCOME TAX

For the six months ended 30 June 2022, the Group's income tax expense is primarily attributable to the following entities:

China: 25% (2021: 25%)

Hong Kong: 16.5% (2021: 16.5%)

Malaysia: 23% (2021: 23%)

Other countries: 20.6% (2021: 20.6%)

The Group's effective tax rate for the six months ended 30 June 2022 is 26.5% (2021: 25.17%).

	For the six months ended	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(Audited)
C	603,241	451,937
D	(94,155)	98,710
Total	509,086	550,647

11. DIVIDENDS

For the six months ended 30 June 2022, the Group has not declared any dividends (2021: Nil).

The Group's dividend policy is to distribute dividends to its shareholders based on its financial performance and cash flow. The Board of Directors has the authority to declare dividends.

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

12. EARNINGS PER SHARE ATTRIBUTABLE TO ORDINARY EQUITY HOLDERS OF THE PARENT

2,562,898,545 (2021: 2,562,898,545)

2,562,898,545 (2021: 2,562,898,545)

For the six months ended
30 June

	2022 RMB'000 (unaudited)	2021 MB'000 ()
Earnings		
	1,553,504	2,482,373
	1,553,504	2,482,373

Number of shares
For the six months ended
30 June

	2022 (unaudited)	2021 ()
Shares		
	2,562,898,545	2,562,898,545
	2,562,898,545	2,562,898,545

G a a a a m 30 J 2022.

Notes to Interim Condensed Consolidated

F a a l 2022

30 June 2022

13. PROPERTY, PLANT AND EQUIPMENT

		For the six months ended 30 June	
		2022	2021
		RMB'000	MB'000
		(Unaudited)	()
Cn	1 Jn	13,011,818	12,579,873
A		1,552,693	1,481,681
A		44,342	790
D		(21,878)	(46,840)
D		(78,349)	(1,434,727)
D		(609,401)	(564,429)
E		(8,555)	(29,439)
Cn	30 J	13,890,670	11,986,909

G ' , n n m n n n MB771,550,000 (31 D m 2021:
MB550,040,000), n - n n n n 16 m

Notes to Interim Condensed Consolidated Financial Statements

30 J 2022

14. TRADE AND BILLS RECEIVABLES (Continued)

		30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
<p>Account receivable: (Note 3)</p>			
WT	1	7,264,653	6,050,772
	2	109,643	129,356
	3	91,882	55,349
	3	125,877	120,136
		7,592,055	6,355,613
L: (Note 4)		(319,488)	(326,380)
		7,272,567	6,029,233
<p>As at 30 J 2022, the carrying amount of trade and bills receivables is MB69,444,000 (31 D 2021: MB99,940,000).</p>			

15. TRADE AND BILLS PAYABLES

		30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
Trade payables		4,862,147	4,515,273
Bills payable		844,934	548,388
		5,707,081	5,063,661
<p>As at 30 J 2022, the carrying amount of trade and bills payables is MB5,707,081 (31 D 2021: MB5,063,661).</p>			

Notes to Interim Condensed Consolidated

F a a | m a

30 June 2022

15. TRADE AND BILLS PAYABLES (Continued)

		30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
A a a a a a a a a a a a :			
<hr/>			
	a a a :		
V	1 a	4,758,515	4,466,889
	2 a	79,408	26,002
	2 3 a	13,503	14,949
	3 a	10,721	7,433
<hr/>			
		4,862,147	4,515,273
<hr/>			

16. INTEREST-BEARING BANK AND OTHER BORROWINGS

		30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
		25,917,685	19,623,059
B a a :	Notes (1)	1,494,670	1,402,634
		24,423,015	18,220,425
<hr/>			
		25,917,685	19,623,059
		600,000	1,200,000
S - m m m a a	(2)	3,084,941	3,686,253
C a	(3)		
<hr/>			
		29,602,626	24,509,312
<hr/>			
		(17,569,068)	(15,460,243)
<hr/>			
N -		12,033,558	9,049,069
<hr/>			

Notes to Interim Condensed Consolidated

F a a | m

30 J 2022

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

A	a	a	a	a	a	a	a	a	
								30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
a a :									
1 a								17,569,068	15,460,243
2 a								4,444,947	4,875,505
2 5 a								5,451,125	1,787,641
5 a								2,137,486	2,385,923
								29,602,626	24,509,312
a a a								(17,569,068)	(15,460,243)
N -								12,033,558	9,049,069

Notes:

(1) Bank loans

a	a	a	a	a	a	a	a	a	a					
m 0.3000% 4.8300% (31 D m 2021: 0.3000% 6.0000%) a m.														
A a 30 J 2022,	a	G	'	a	a	a	a	G	'	a	a	a	m	(13)
a m MB 771,550,000 (31 D m 2021: MB550,040,000), a a a a m - - a a m														
MB511,229,000 (a a a a m - - a 31 D m 2021: MB513,993,000).														
A a 30 J 2022,	a	G	'	a	a	a	a	G	'	a	a	a	a	(14)
a m MB99,940,000 (31 D m 2021: MB69,444,000) a a a m MB8,417,000 (31 D m 2021: MB8,296,000).														
A a 30 J 2022,	G	a		m	a	a	a	m		m	a		(31 D m 2021:	
MB7,742,000).														
A a 30 J 2022,	G			58.67%		a	z	B a a M a		C , L .	a	a	a	(31
D m 2021: 58.67% z B a a).														

16. INTEREST-BEARING BANK AND OTHER BORROWINGS (Continued)

Notes: (Continued)

(2) Super Short-term Commercial Paper

13 A	2022,	C m	-	m m m	v v	v v	v v m	MB600,000,000,	v	v 2.65%
v m.			-	m m m	v v	v v	m	11 A	2022.	

(3) Corporate bonds

13 A	2018,	C m	v	v m	v v v	v v v	v v m	MB1,300,000,000,	v
v 3.50%	v m.		v v v v	v v v	m	v	13 A	2023. A v 30 J	2022,
- v	v		MB746,651,000.						v
30 N	m 2018,	C m	v	v m	v v v	v v v	v v m	MB500,000,000,	v
v 3.83%	v m.		v v v v	v v v	m	v	30 N	m 2022. A v 30 J	2022,
- v	v		MB239,848,000.						v
2 F	v 2021,	C m	v	v m	v v v	v v v	v v m	MB1,600,000,000,	v
v 3.98%	v m.		v v v v	v v v	m	v	2 F	v 2025. S	v
v m	v , v		, v	, C m	v	v	v	v	v v
v m	v		- v v (v m 2023),	v	v	v	v	v	v v 30 J
2022. A v 30 J	2022,	v	- v v		MB1,599,242,000.				v
9 M	2022,	C m	m m m	v m	v v v	v v v	v v m	MB500,000,000,	v
v 3.50%	v m.		v v v v	v v v	m	v	9 M	2026. A v 30 J	2022,
- v	v		MB499,200,000.						v

17. BUSINESS COMBINATION

20 J v 2022, S v v F H v (G) C ., L ., v v C m v , v 70%
 G v v C ., L . * (廣州新市醫院有限公司) (H v) m v v .
 v v v MB 809,200,000. A v , G 70%
 H v .

* E v m m v C m v m v m C m v v v
 C v m m v .

Notes to Interim Condensed Consolidated

F a a | a a

30 J 2022

17. BUSINESS COMBINATION (Continued)

a a a a a a a a a a a a a a a a

Notes to Interim Condensed Consolidated

F n n | m n

30 J 2022

18. DISPOSAL OF SUBSIDIARIES

D m 30 J 2022, G n n m n n n
 H n A M n n C .,L . A n n n n n C .,L , 51%
 J n H n n n n C .,L .* (江蘇黃河藥業股份有限公司), n n
 MB125,328,000. n n 3 J n n 2022. n n n n n
 n m G n .

D m 30 J 2022, G n n m n n n G n
 (n) C .,L ., 100% n n n B n n C .,L .*
 (上海輸血技術有限公司), n n MB390,000,000. n n 28 F n 2022.
 n n n n n n G n .

*

Notes to Interim Condensed Consolidated

F a a l m a

30 June 2022

18. DISPOSAL OF SUBSIDIARIES (Continued)

A a a		a a a a		a a a		:	MB'000
C a	a						421,905
C a		a	a				319,220
C a	a	a	a a				(36,632)
N		a a a	a		a	a	704,493

19. COMMITMENTS

G a		a a m m m a		:	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
C a ,	:				2,415,887	2,127,421
I m	a a m				2,487,233	2,066,497
I m	F a a a a a a a				513,177	451,933
A	:				2,544,064	3,128,531
					7,960,361	7,774,382

Notes to Interim Condensed Consolidated

F a n a l m a

30 J 2022

20. RELATED PARTY TRANSACTIONS

(a) Sales of pharmaceutical products and services

	For the six months ended	
	2022	2021
	RMB'000	MB'000
	(Unaudited)	(a)
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 6 & 15)	2,210,042	1,809,891
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 16)	365,650	326,501
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	11,744	40
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	4,670	5,139
Fosun Pharmaceutical (Group) Co., Ltd. (notes 2 & 4)	3,222	2,030
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	2,930	7,936
Fosun Pharmaceutical (Group) Co., Ltd. (notes 3 & 4 & 10 & 16)	2,749	252
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	2,335	2,436
Jiangsu Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	537	1,251
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	447	6
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 6)	179	2,039
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 2 & 4)	123	671
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	57	
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 7)	19	19
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	10	26
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8 & 17)	5	6
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4 & 18)	—	637
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8 & 19)	—	148
Fosun Pharmaceutical (Group) Co., Ltd. (notes 4 & 8)	—	4
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (notes 1 & 4)	—	3
	2,604,719	2,159,035

Notes to Interim Condensed Consolidated

F a a | ୩୩

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(b) Purchase of pharmaceutical products and services

	For the six months ended	
	30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
ଈ ା ମା G C ., L . ା (notes 4 & 6 & 15)	168,498	178,674
F I ା ା L ମ ା (notes 3 & 4 & 11 & 16)	72,128	22,575
C . ା ମା ା H C ., L . A (notes 1 & 4 & 16)	19,470	18,434
F H ା I ା ., L . (notes 4 & 8)	12,854	627
F N ା (ଈ) M ା C ., L . (notes 4 & 6)	8,892	
E I ମ ା M ା ମ (ଈ ା) C ., L . (notes 4 & 7)	5,407	
ଈ ା ା B ମ ା , I . (notes 1 & 4)	3,204	12,041
A ଈ ା ା ମା ା E C ., L . (notes 1 & 4)	632	1,034
ଈ NN AM ା ଈ & C ., L . (notes 1 & 4)	179	1,306
ଈ ା V ା L ା I ମା C ., L . (notes 1 & 4)	3	55
G ା C ମ ା L . (notes 4 & 8 & 19)	—	34,544
H ା ା H ା M ା ମ C ., L . (notes 1 & 4)	—	105
	291,267	269,395

(c) Leasing and property management services

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(c) Leasing and property management services (Continued)

As lessee

For the six months ended 30 June 2022

Types of leased assets		Rental charges for short-term/low-value assets leases	Additions of right-of-use assets
F a a L m a	a		
(notes 3 & 5 & 13 & 16)	a a	9,454	23,569

For the six months ended 30 June 2021

		a a	
		- m/	A
		- a	- -
	a a	a a	a
F a a L m a	a		
(notes 3 & 5 & 13 & 16)	a a	5,242	
D a a a a	LL (notes 5 & 8 & 19)	114	
sh a a	LL (notes 5 & 8 & 19)	41	
		5,397	

For the six months ended
30 June

	2022 RMB'000 (Unaudited)	2021 MB'000 ()
Property management services		
F a a L m a		
(notes 3 & 5 & 14 & 16)	11,732	6,818

Notes to Interim Condensed Consolidated

F a a | m a

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to a related parties

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
Deposits in Fosun Finance		
F F a (notes 3 & 16)	870,551	974,576
Loans from Fosun Finance		
F F a (notes 3 & 16)	111,686	116,127
Loans to Fosun Kite Biological Technology Co., Ltd		
<p> 2018 12 2019 16 2022.D A 30 J 2022, MB 113,000(31 D 2021: MB 188,840,000), MB 138,445,000(31 D 2021: MB 301,000). </p>		
F K B a C ., L (note 2)	138,558	189,141

Notes to Interim Condensed Consolidated

F a r E a s t

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans to Nature's Sunshine (Far East) Limited

Far East Nature's Sunshine (Far East) Limited (Far East) Limited (note 1)
 2022. D 2021. G
 MB1,927,000
 3%
 MB1,927,000.

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
Far East Nature's Sunshine (Far East) Limited (note 1)	—	1,927

Loans to StarKids Children's Hospital Shanghai

StarKids Children's Hospital Shanghai (StarKids Children's Hospital Shanghai) (note 1)
 2022. A 30 J 2021. A 30 J
 MB9,291,000
 MB273,000(31 D 2021: MB94,000).

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
StarKids Children's Hospital Shanghai (note 1)	9,564	9,385

Loans to Shanghai Xingmai Information Technology Co., Ltd.

Shanghai Xingmai Information Technology Co., Ltd. (Shanghai Xingmai Information Technology Co., Ltd.) (note 1)
 2022. D 2021. A 29
 MB71,400,000
 10%
 MB1,864,000.

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
Shanghai Xingmai Information Technology Co., Ltd. (note 1)	—	73,264

20. RELATED PARTY TRANSACTIONS (Continued)

(d) Loans from/to related parties (Continued)

Loans from Shanghai Youle Information Technology Co., Ltd.

གྲོ་བ་ལྷན་ཁག་གི་ལོ་ལོ་མཉམན་ལོན་གྱི་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ MB5,492,000 རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་
 (ཨོ་ལོ་ལོ་མཉམན་ལོན་) རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 4.35%. རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 19 2021 18
 2022. A རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 2022, རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ MB160,000 (31 D རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 2021: MB40,000).

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
ཨོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (note 3)	5,652	5,532

Loans from Shanghai Fosun High Tech (Group) Company limited

གྲོ་བ་ལྷན་ཁག་གི་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ MB18,673,000 རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་
 (ཨོ་ལོ་ལོ་མཉམན་ལོན་) རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 4.35%. རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 19 2021 18
 2022. A རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 2022, རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ MB543,000 (31 D རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ 2021: MB137,000).

	30 June 2022 RMB'000 (Unaudited)	31 D 2021 MB'000 (A)
ཨོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (note 3)	19,216	18,810

(e) Interest income from/interest expense to related parties

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (A)
Interest income		
F K B རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (note 2)	4,248	4,678
F F རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (notes 3 & 16)	4,026	4,560
ཨོ་ལོ་ལོ་མཉམན་ལོན་ རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (note 1)	180	182
Na ' ཨོ་ལོ་ལོ་མཉམན་ལོན་ (F a E a) རྒྱ་ཡི་ཧོ་ལོ་ལོ་མཉམན་ལོན་ (note 1)	14	112
	8,468	9,532

Notes to Interim Condensed Consolidated

F a n a l r e p o r t

30 J u n e 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(e) Interest income from/interest expense to related parties (Continued)

	2022	2021
Interest income from related parties	0.35% (F o r 30 J u n e 2022)	0.35% (F o r 30 J u n e 2021)
Interest expense to related parties	1.485%-1.89% (F o r 30 J u n e 2022)	1.89% (F o r 30 J u n e 2021)
Interest income from related parties	1.15% (F o r 30 J u n e 2022)	1.15% (F o r 30 J u n e 2021)
Interest expense to related parties	1.55% - 1.755% (F o r 30 J u n e 2022)	1.55% - 1.755% (F o r 30 J u n e 2021)

Interest expense	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 (a u d i t e d)
F i n a n c i n g (n o t e s 3 & 16)	2,666	1,432
U t i l i t i e s (G a s) C o n s u m p t i o n (n o t e s 3 & 16)	406	
U t i l i t i e s I n t e r n e t C o n n e c t i o n L e n d i n g (n o t e s 3 & 16)	119	
	3,191	1,432

Notes:

- (1) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (2) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (3) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (4) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (5) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (6) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (7) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (8) Interest income from related parties is primarily from the sale of pharmaceutical products to related parties.
- (9) In A u g u s t 2021, C o n s u m p t i o n C o n t r a c t H o l d i n g s , F o r H a n s , F o r C o n s u m p t i o n C o n t r a c t H o l d i n g s

Notes to Interim Condensed Consolidated

F a a | m

30 J 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(g) Donations

	Six months ended 30 June	
	2022 RMB'000 (Unaudited)	2021 MB'000 ()
...	7,502	8,708

F m 30 J 2022, G a MB7,502,000 (m 30 J 2021: MB8,708,000) a a a a a a .

(h) Outstanding balances with related parties:

- () A a 30 J 2022, G a a a a m m a a a a MB1,705,659,000 (31 D m 2021: MB1,725,786,000). a a , - a a m , F F a .
- () A a 30 J 2022, G a a a a m a a m a a a MB1,016,575,000 (31 D m 2021: MB994,289,000). a a , - a a a m , a Na ' S (Fa Ea) L m a S a K C ' H a S a a .
- () A a 30 J 2022, a a m a a a MB143,923,000 (31 D m 2021: MB194,222,000) , - a a a m , a F K .
- () A a 30 J 2022, a a m a a m MB11,869,000 (31 D m 2021: MB10,856,000) , - a a a a m .
- () A a 30 J 2022, G a a a a m a a m a a a MB216,497,000 (31 D m 2021: MB197,757,000). a a , - a a a m a m , m S a a I m a C , L , F F a a S a a F H (G) C m a L m .
- () A a 30 J 2022, a a a a m a a a MB312,662,000 (31 D m 2021: MB317,922,000) a a , - a a a m a m .
- () A a 30 J 2022, a a a a m a a a MB6,696,000 (31 D m 2021: MB6,696,000) a - a a , , - a a a m a m .

Notes to Interim Condensed Consolidated

F a a | m

30 June 2022

20. RELATED PARTY TRANSACTIONS (Continued)

(h) Outstanding balances with related parties: (Continued)

() A 30 J 2022, 33 33 33 33 MB107,000 (31 D 2021: MB419,000) 33 33 33 33

() C 33 33 G 33 33 33 33 33 33 33 33

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS

33 33 33 33 G 33 33 33 33 33 33 33 33

	Carrying amounts		Fair values	
	30 June 2022	31 D 2021	30 June 2022	31 D 2021
	RMB'000 (Unaudited)	MB'000 (A)	RMB'000 (Unaudited)	MB'000 (A)
Financial Assets:				
E 33 33 33 33 33	21,795	29,916	21,795	29,916
D 33 33 33 33 33	554,168	427,884	554,168	427,884
F 33 33 33 33 33	4,021,584	5,447,558	4,021,584	5,447,558
33 33 -	77,469	77,395	78,394	78,319
	4,675,016	5,982,753	4,675,941	5,983,677
Financial Liabilities:				
N - 33 33 33	10,787,707	6,694,183	10,690,730	6,599,603
(33 33 33)	3,084,941	3,686,254	3,084,632	3,654,328
F 33 33 33 - 33	2,342,067	1,944,174	2,342,067	1,944,174
	16,214,715	12,324,611	16,117,429	12,198,105

Notes to Interim Condensed Consolidated

Fair Value

30 J 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

G
A
B
D
B
G 30 J 2022									

D
B
B 30 J 2022									

Unobservable inputs for Level 3 assets

F
L 3									

Unobservable inputs for Level 3 liabilities

Σ
Σ

Notes to Interim Condensed Consolidated

F a a | m a

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy

a a a a m a m a G ' a a m :

Assets measured at fair value:

As at 30 June 2022 (Unaudited)

	Quoted prices in active markets (Level 1) RMB'000	Fair value measurement using Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	Total RMB'000
F a a a a a a	1,924,337	389,335	1,707,912	4,021,584
E m a a a a	4,073	17,722	—	21,795
D m a a a	—	554,168	—	554,168
	1,928,410	961,225	1,707,912	4,597,547

As at 31 December 2021 (Audited)

	Fa a m a m a a a a	(L 1) MB'000	(L 2) MB'000	(L 3) MB'000	a MB'000
F a a a a a a		3,259,068	573,994	1,614,496	5,447,558
E m a a a a		5,380	24,536	—	29,916
D m a a a		—	427,884	—	427,884
		3,264,448	1,026,414	1,614,496	5,905,358

Notes to Interim Condensed Consolidated

F a a | m

30 J 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Assets measured at fair value: (Continued)

m m a a m a m L 3 a a :

For the six months ended 30 June 2022

	Financial assets at fair value through profit and loss RMB'000 (Unaudited)	Equity investments Designated at fair value through other comprehensive income RMB'000 (Unaudited)
A a 1 J a 2022	1,614,496	—
a	(31,879)	—
a a a m a	121,970	—
a a m m a	42,586	—
A	340,981	—
D a	(380,242)	—
A a 30 J 2022	1,707,912	—

For the six months ended 30 June 2021

F a a
a
a a a
a

Notes to Interim Condensed Consolidated

F a a l m a

30 June 2022

21. FAIR VALUE AND FAIR VALUE HIERARCHY OF FINANCIAL INSTRUMENTS (Continued)

Fair value hierarchy (Continued)

Liabilities measured at fair value:

As at 30 June 2022 (Unaudited)

	RMB'000	Fair value measurement using			Total RMB'000
		Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Am	m a	—	—	2,152,663	2,152,663

As at 31 December 2021 (Audited)

	RMB'000	Fair value measurement using			Total RMB'000
		Quoted prices in active Markets (Level 1) RMB'000	Significant observable inputs (Level 2) RMB'000	Significant unobservable inputs (Level 3) RMB'000	
Am	m a			1,729,070	1,729,070

m m 48 MB-1.444 a (m a m) 8-480 3 a 596227 a a :6 0 1 79.37 266.1372 m 0 0 m 337.323 0 s
1,729,070 1 MB-1.444 () 10.265 a a -5.659'000

Notes to Interim Condensed Consolidated

F a a | m a

30 J 2022

22. CONTINGENT LIABILITIES

A a 30 J 2022 a 31 D m 2021, G a a a .

23. EVENTS AFTER THE REPORTING PERIOD

Non-public offering of A shares

I J 2022, C m a 106,756,666 A- a 10 a - a a
 MB42.00 a , a a a m a a MB4,483,779,972.00. a a
 A- a m a a a B a C a a D a C a
 C a L m 27 J 2022. A- a a a a a - . a
 a a a a 6 m m a m a a a .

24. APPROVAL OF THE INTERIM CONDENSED CONSOLIDATED FINANCIAL STATEMENTS

m a a a a m a a a a D
 29 A 2022.

Definitions

Interim Report	Interim Report	Interim Report
%		
ADC	ADC	ADC
Amended	Amended	Amended
Amendment	Amendment	Amendment
Amendment ()	Amendment ()	Amendment ()
Amendment A	Amendment A	Amendment A
Amendment B	Amendment B	Amendment B
Amendment C	Amendment C	Amendment C
BIC	BIC	BIC

Definitions

C.S.C	C.S.C	中國證券監督管理委員會
D	D	
D	D	
E	E	
E	E	
E	E	
FIC	F	
F	F	
F	F	
F	F	
F	F	
F	F	

Definitions

I F HK	I 蘇 復 星 (H K) C ., L ., 有 限 公 司	H K 復 星 醫 藥 有 限 公 司
I F 蘇 復 星	I 蘇 復 星 M 復 星 (蘇 復 星) C ., L . * (直 觀 復 星 醫 療 器 械 技 術 (上 海)有 限 公 司), 有 限 公 司	C 蘇 復 星
I F	I F HK 復 星 I F 蘇 復 星	
K 復 星	K E C ., 有 限 公 司	N 復 星
M 復 星	M 復 星 蘇 復 星 A 復 星	C
M	M E C K S H A & D H M E C ., 有 限 公 司	蘇 復 星
M C		

Definitions

H	新市醫院有限公司	G	廣州新市醫院有限公司 (廣州新市醫院有限公司) (廣州新市醫院有限公司)	H	新市醫院有限公司 (廣州新市醫院有限公司)
		G	廣東藥科大學附屬第三醫院		A
		C	廣東藥科大學附屬第三醫院		H
F	徐州風友匯藥品零售有限公司	F	徐州風友匯藥品零售有限公司 (徐州風友匯藥品零售有限公司)		
			2022		
B	亞能生物技術(深圳)有限公司	B	亞能生物技術(深圳)有限公司 (亞能生物技術(深圳)有限公司)		
		C	重慶藥友製藥有限責任公司		
I	重慶藥友製藥有限責任公司	C	重慶藥友製藥有限責任公司 (重慶藥友製藥有限責任公司)		
*	F				